Cardiovascular system

These ingredients are often used in alternative medicine to support cardiovascular system.

• acaciaScientific

  Acacia gum has been tested in multiple RCTs for cardiovascular risk factors: it reduces LDL cholesterol, total cholesterol, triglycerides, and blood pressure, and decreases visceral adiposity index. A dedicated metabolic syndrome RCT (12 weeks, 20 g/day) found significant improvements in blood pressure, fasting glucose, and body composition as cardiovascular risk markers.

• acai berryScientific

  Acai berry has documented effects on multiple cardiovascular parameters including endothelial function, vascular tone, and lipid profiles, supported by both clinical and preclinical evidence. Polyphenols activate eNOS, reduce LDL oxidation, and modulate inflammatory pathways central to cardiovascular disease. Human trials demonstrate improvements in vascular function and select lipid markers.

• acetyl-L-carnitineScientific

  L-carnitine and ALC have been studied extensively in cardiovascular disease. A meta-analysis of 13 RCTs found L-carnitine associated with significant reductions in mortality, ventricular arrhythmias, and angina after acute myocardial infarction. Clinical trials also support ALC in peripheral arterial disease and ischemic heart conditions, with beneficial effects on cardiac energy metabolism via facilitation of fatty acid oxidation.

• activated charcoalScientific

  In CKD patients, oral activated charcoal reduces circulating indoxyl sulfate (IS), a uremic toxin that promotes vascular smooth muscle cell oxidative stress, endothelial dysfunction, and atherosclerosis. A 12-month RCT in stage 3–4 CKD patients showed oral AC delayed the development and progression of coronary artery vascular calcification. Animal models with renal dysfunction further confirm AC's attenuation of atherosclerosis extent and plaque instability.

• adzuki beanScientific

  Adzuki bean polyphenol extract improved HDL-C in a human RCT, while animal studies demonstrate reductions in systolic blood pressure, ACE activity, vascular oxidative stress, and aortic lesion. Dietary fiber and potassium content further support cardiovascular function. Evidence spans human and animal research.

• ajoeneScientific

  Ajoene exerts multiple documented effects on the cardiovascular system: irreversible and reversible inhibition of platelet aggregation via GPIIb/IIIa blockade, prevention of thrombus formation in ex vivo and animal models, inhibition of arterial smooth muscle cell proliferation, and suppression of cholesterol biosynthesis. These converging mechanisms position ajoene as a multi-target cardiovascular compound.

• ajwainScientific

  Ajwain acts on the cardiovascular system via multiple documented pharmacological mechanisms: calcium channel-blocking antihypertensive effects of thymol, hypolipidemic effects reducing atherogenic lipids, and antiplatelet activity documented in human platelets. A human RCT in hypertensive patients has been conducted.

• AKG (alpha-ketoglutarate)Scientific

  AKG has been shown to enhance endothelial nitric oxide synthesis, improve whole-body insulin sensitivity, and protect against hyperlipidemia-induced endothelial damage in animal models. A PMC study found that AKG enhanced nitric oxide production in obese rats and improved vascular insulin sensitivity, with noted cardiovascular relevance. AKG is also used in cardiac surgery cardioplegia solutions.

• akkermansia muciniphilaScientific

  A. muciniphila reduces cardiometabolic risk factors including total cholesterol and insulin resistance in human RCT data, and attenuates vascular endothelial inflammation and atherosclerotic lesion progression in animal models. Its abundance is inversely correlated with hypertension in human epidemiological studies. Mechanisms include LPS translocation reduction, SCFA-mediated cholesterol biosynthesis inhibition, and direct vascular anti-inflammatory effects.

• ALA (alpha-linolenic acid)Scientific

  ALA is an essential plant omega-3 with well-documented cardioprotective effects, including lipid modulation, blood pressure reduction, anti-platelet activity, and reduction of vascular inflammation. Multiple large dietary RCTs and epidemiological studies support its role in cardiovascular health.

• ALA (alpha-lipoic acid)Scientific

  Alpha-Lipoic Acid (ALA) has meaningful clinical evidence supporting a role in cardiovascular health, primarily through antioxidant and anti-inflammatory mechanisms that improve endothelial function and reduce key cardiovascular risk markers. Multiple RCTs and meta-analyses confirm effects on endothelial function (flow-mediated dilation), inflammatory markers (CRP, IL-6, TNF-α), and cardiometabolic parameters such as triglycerides and blood glucose. Effects on blood pressure are inconsistent across trials, and some outcomes (HDL, LDL, SBP, DBP) show no significant benefit in large meta-analyses. Overall, evidence is promising but not yet conclusive for clinical cardiovascular endpoints.

• alfalfaScientific

  Alfalfa's saponins, flavonoids, and phytoestrogens interact with the cardiovascular system through lipid-lowering, anti-atherogenic, anti-inflammatory, and antioxidant mechanisms. Human clinical evidence supports LDL and apoB reduction. Primate studies show atherosclerosis regression.

• algal oilScientific

  Algal oil DHA supports the cardiovascular system by lowering triglycerides, raising HDL-cholesterol, reducing blood pressure, improving arterial compliance, and inhibiting platelet aggregation. A meta-analysis of 11 algal DHA RCTs confirmed significant triglyceride lowering and lipoprotein improvements. Broader marine omega-3 RCT data (n=127,477) show reductions in myocardial infarction and cardiovascular death.

• alginic acidScientific

  Alginate's potential to lower cholesterol and reduce dietary fat and lipid absorption through pancreatic lipase inhibition and bile acid binding is relevant to cardiovascular risk reduction. Animal studies document reduced TG and LDL-C, and some human data on lipid metabolism exist. Microbiome-mediated SCFA production from alginate fermentation also affects cardiometabolic markers.

• allspiceScientific

  Animal studies demonstrate significant dose-related hypotensive activity of P. dioica aqueous extract via CNS depression and possible vasorelaxation. Polyphenols including quercetin and eugenol have cardiovascular-relevant antioxidant and vasodilatory properties demonstrated in vitro. No human cardiovascular trials exist.

• almondScientific

  Almonds have extensive clinical evidence supporting cardiovascular system health, including significant LDL cholesterol reduction, modest diastolic blood pressure lowering, improved endothelial function, reduced oxidized LDL, and favorable effects on lipoprotein(a). The FDA has issued a qualified health claim for nuts including almonds in relation to coronary artery disease.

• aloe veraScientific

  Aloe vera demonstrates clinically documented beneficial effects on cardiovascular risk factors including triglycerides, total cholesterol, LDL-C, and HDL-C in RCTs. Its anti-inflammatory properties targeting TNF-α and IL-6 are also relevant to cardiovascular risk reduction. Aloe species have traditional use for hypertension, though direct human BP trial evidence with aloe vera specifically is limited.

• alpha D-ribofuranoseScientific

  D-ribose has been investigated in multiple clinical trials for ischemic cardiovascular disease, demonstrating benefits in diastolic function, exercise-induced ischemia tolerance, and quality of life in CAD and CHF patients. The mechanism centers on replenishment of myocardial ATP depleted by ischemia.

• alpha-caroteneScientific

  Serum alpha-carotene is inversely associated with cardiovascular disease prevalence and mortality across multiple large prospective and cross-sectional studies. A NHANES cross-sectional study (N=12,424) found the highest quartile of serum alpha-carotene associated with OR=0.61 (95% CI 0.47–0.79) for CVD. Dutch and Japanese long-term cohorts corroborate alpha-carotene's specific inverse association with CVD mortality independent of other antioxidants.

• alpha-glycosyl isoquercitrinScientific

  Human RCT evidence shows AGIQ significantly improves endothelial function in adults at cardiovascular risk. Preclinical data and pharmacology reviews document anti-anaphylactic cardiovascular protection, vasodilatory, and antioxidant vascular effects. AGIQ metabolizes to quercetin, a well-documented cardiovascular-protective flavonoid.

• amaranthScientific

  Amaranth exerts multiple beneficial effects on the cardiovascular system through cholesterol modulation, blood pressure reduction via ACE-inhibitory peptides, antioxidant protection of blood vessels, and direct clinical evidence from a 125-patient RCT in coronary heart disease and hypertension patients. Squalene, polyunsaturated fatty acids, tocopherols, phytosterols, and bioactive peptides all contribute to cardiovascular benefit.

• anchoviesScientific

  Anchovies provide EPA, DHA, selenium, niacin, and potassium — a combination with multiple documented effects on the cardiovascular system including triglyceride lowering, blood pressure reduction, anti-inflammatory and antithrombotic action, and reduced cardiovascular mortality. Meta-analyses of RCTs confirm significant cardiovascular outcome benefits from omega-3 fatty acid intake at levels achievable from regular anchovy consumption.

• andrographisScientific

  Andrographis demonstrates scientifically documented activity on the cardiovascular system primarily through antiplatelet and antithrombotic mechanisms. Human in vitro platelet studies and an ex vivo clinical study in 63 cardiac/cerebrovascular patients support antiplatelet activity. Antihypertensive and anti-atherosclerotic activities are also documented preclinically.

• anemarrhena asphodeloidesScientific

  Anemarrhena steroidal saponins (timosaponin B-II, AIII, and related compounds) demonstrate anti-platelet aggregation in human blood, cardioprotective effects in isoproterenol-induced myocardial infarction in rats, and blood pressure-lowering effects in animal models. Mangiferin activates PPAR-α relevant to lipid metabolism.

• annattoScientific

  Annatto-derived delta-tocotrienol has demonstrated clinical benefits on cardiovascular risk factors including LDL cholesterol, total cholesterol, triglycerides, blood pressure, and inflammatory biomarkers (CRP, TNF-α, IL-6) in multiple RCTs. The mechanism involves HMG-CoA reductase inhibition and NF-κB suppression. Traditional use of annatto seeds as a cardiotonic is documented in Latin American indigenous medicine.

• appleScientific

  Apple consumption and apple-derived polyphenols have been extensively studied for cardiovascular effects including cholesterol reduction, blood pressure lowering, endothelial function improvement, and reduced CVD event risk in epidemiological cohorts and multiple RCTs.

• apple cider vinegarScientific

  ACV exerts clinically documented effects on multiple cardiovascular risk markers: total cholesterol, LDL, triglycerides, fasting blood glucose, and HbA1c, all confirmed in meta-analyses of RCTs. Modest, inconsistent blood pressure effects have also been reported. No direct cardiovascular event (MI, stroke) outcome data exist in humans.

• apricotScientific

  Apricot provides multiple cardiovascular-protective nutrients and bioactives: potassium (blood pressure regulation), soluble fiber (cholesterol lowering), polyphenols (endothelial protection and anti-inflammatory effects), and carotenoids (antioxidant protection against LDL oxidation). Human clinical trials on bitter apricot seeds have demonstrated improvements in LDL-C and atherogenic lipoprotein subfractions. Overall evidence for cardiovascular benefit is substantial.

• argan nut oilScientific

  Argan oil is the best-evidenced in cardiovascular health. Meta-analysis of 5 RCTs (n=292) confirms significant improvements in total cholesterol, LDL-C, HDL-C, and triglycerides. Additional human trials demonstrate reduced LDL oxidation, improved paraoxonase activity, and reduced platelet aggregation.

• arginine alpha ketoglutarateScientific

  AAKG acts on the cardiovascular system primarily through NO-mediated vasodilation: the arginine component is the substrate for eNOS in endothelial cells, and AKG enhances endothelial NO synthesis and reduces vascular oxidative stress. Clinical studies confirm AAKG raises plasma arginine and the arginine:ADMA ratio, key determinants of cardiovascular NO bioavailability.

• arjunaScientific

  Arjuna (Terminalia arjuna) stem bark has been used in Ayurveda for cardiac disorders for centuries, and this traditional use is supported by multiple human clinical trials. Studies have demonstrated benefits in chronic stable angina, congestive heart failure, and coronary artery disease. Evidence quality is moderate—trials are generally small and conducted primarily in India—but the body of evidence is sufficient to classify the link as scientific.

• aronia melanocarpaScientific

  Aronia melanocarpa exerts broad effects on the cardiovascular system including reductions in blood pressure, total and LDL cholesterol, triglycerides, and platelet aggregation in multiple human clinical trials. Mechanistic pathways include ACE inhibition, antioxidant protection of the vascular endothelium, inhibition of ICAM-1/VCAM-1 adhesion molecules, and antiplatelet effects via ADP-pathway modulation.

• artichokeScientific

  Artichoke leaf extract (ALE) has been investigated in multiple randomized controlled trials and meta-analyses for cardiovascular benefit, primarily through lipid-lowering effects. A 2017 meta-analysis of 9 RCTs (702 subjects) found significant reductions in total cholesterol, LDL-C, and triglycerides. A 2025 systematic review further confirmed reductions in systolic and diastolic blood pressure alongside lipid improvements. The bioactive constituents—luteolin, cynarin, and chlorogenic acid—act via HMG-CoA reductase inhibition, increased bile secretion, and antioxidant protection of LDL particles.

• ashitabaScientific

  Ashitaba demonstrates preclinical cardiovascular activity across multiple mechanisms: antihypertensive effects via chalcone 4-HD in hypertensive rats, anti-platelet and anti-PAI-1 effects reducing thrombotic risk, and DMC protecting mice from myocardial ischaemia via autophagy. The OBM ICM review concludes ashitaba holds promise against cardiovascular disease linked to metabolic syndrome.

• ashwagandhaScientific

  Ashwagandha has demonstrated multiple cardiovascular effects in clinical studies: blood pressure reduction, lipid profile improvement, anti-inflammatory effects on the vascular endothelium, and antioxidant cardioprotection. A 2024 PubMed review specifically examined its effects on vascular endothelium, inflammation, lipid metabolism, and cardiovascular outcomes.

• astaxanthinScientific

  Astaxanthin, a xanthophyll carotenoid, has demonstrated cardiovascular-relevant effects in human clinical studies, including reductions in LDL cholesterol, total cholesterol, and oxidative stress biomarkers. A 2023 randomized placebo-controlled trial in adults with prediabetes and dyslipidaemia found significant decreases in LDL and total cholesterol after 24 weeks of supplementation at 12 mg/day. A 2021 meta-analysis found modest but clinically suggestive reductions in diastolic blood pressure in patient subgroups. Evidence is promising but overall still limited by small sample sizes and the absence of large cardiovascular outcome trials.

• astragalusScientific

  Astragalus membranaceus and AS-IV have documented cardioprotective, vasoprotective, antihypertensive, and lipid-modulating activity. Clinical studies show benefits in heart failure, ischemic heart disease, and angina. Multiple systematic reviews confirm anti-inflammatory, antioxidant, and antifibrotic mechanisms protecting the heart and vasculature.

• ATP (adenosine triphosphate)Scientific

  ATP disodium supplementation has demonstrated clinical benefits across multiple cardiovascular parameters including blood flow, vascular diameter, heart rate variability, and blood pressure in human trials. ATP acts via endothelial P2Y receptors to promote vasodilation through NO, prostacyclin, and EDHF pathways. The 2021 review by Freitas et al. identifies cardiovascular health as a primary evidence-supported benefit of oral ATP disodium.

• bacillus coagulansScientific

  B. coagulans has documented cholesterol-lowering activity (total cholesterol, LDL reduction, HDL increase) in a hypolipidemia clinical study with SNZ 1969, as well as in vitro evidence from MTCC 5856. Anti-inflammatory effects (CRP reduction in the RA RCT) are also relevant to cardiovascular health.

• baikal skullcapScientific

  S. baicalensis has documented clinical use in China for hypertension and cardiovascular disease. Baicalin lowers blood pressure in animal hypertension models, inhibits myocardial apoptosis and inflammation, and reduces vascular oxidative stress. Preclinical evidence for cardiovascular protection is robust, with supporting clinical data from Chinese practice.

• bambooScientific

  Bamboo extract and bamboo shoot preparations affect multiple cardiovascular parameters including blood pressure, cholesterol, triglycerides, and inflammatory chemokines associated with atherosclerosis. Biomedical research documents cardiovascular disease protection as a principal documented effect of bamboo-derived products. TCM additionally uses bamboo to promote circulation.

• banabaScientific

  Banaba and its principal active corosolic acid exert multi-target favorable effects on cardiovascular risk factors including blood pressure, dyslipidemia, oxidative stress, and inflammation in animal models. A human RCT confirmed significant systolic blood pressure reduction. Banaba extract has also been included in human cardiovascular nutraceutical trials addressing cholesterol and glucose metabolism.

• bananaScientific

  Banana supports cardiovascular health through potassium (blood pressure reduction), soluble fiber (LDL reduction), and polyphenols (anti-atherosclerotic, anti-platelet, and anti-inflammatory effects). Large cohort data link potassium intake from foods like bananas to reduced stroke risk and fewer major cardiovascular events. Banana bioactive compounds display multiple cardioprotective mechanisms.

• baobabScientific

  Baobab's cardiovascular system relevance spans multiple mechanisms including LDL-cholesterol reduction via soluble fiber, polyphenol-mediated inhibition of HMG-CoA reductase and pancreatic lipase (in silico), antioxidant protection of vascular endothelium, and attenuation of postprandial hyperglycemia in human RCTs. An ongoing registered RCT will measure lipid profiles, blood pressure, and inflammatory markers in humans with obesity.

• barberryScientific

  Barberry exerts multiple cardiovascular benefits supported by human clinical evidence, including significant reductions in LDL cholesterol, triglycerides, total cholesterol, and blood pressure, plus antiarrhythmic and cardioprotective effects of berberine and berbamine alkaloids.

• barleyScientific

  Barley β-glucan exerts well-documented cardiovascular effects including significant LDL and total cholesterol reduction, non-HDL cholesterol reduction, blood pressure lowering, and gut microbiome shifts associated with reduced CVD risk. FDA, EFSA, and Health Canada have all issued health claims for barley's cardiovascular role.

• barrenwortScientific

  Epimedium and icariin act on multiple cardiovascular targets including eNOS upregulation, NO-dependent vasorelaxation, anti-atherosclerotic and anti-thrombotic effects, and cardioprotection in heart failure models. Human subject data confirm positive effects on vascular reactivity and endothelial function. Traditional TCM use includes coronary heart disease and hypertension.

• basilScientific

  Basil affects the cardiovascular system through multiple documented mechanisms: calcium channel blockade by eugenol lowers blood pressure, polyphenols reduce total cholesterol and LDL while raising HDL, and antioxidant constituents protect against lipid oxidation and atherosclerosis. Clinical trial evidence supports lipid and blood pressure effects.

• bayberryScientific

  Bayberry has been evaluated for cardiovascular effects at the molecular level. A potent non-peptide endothelin-A receptor antagonist (myriceron caffeoyl ester) was isolated from Myrica cerifera in a landmark 1992 in vitro study. Myricitrin has been shown to inhibit vascular adhesion molecule expression and protect cardiomyocytes in animal models. Human evidence is limited to indirect cardiovascular markers in one small NAFLD trial.

• bee pollenScientific

  Bee pollen's polyphenols reduce ACE activity, angiotensin II, ox-LDL, and atherosclerotic vascular changes in animal models. Fermented bee pollen postbiotics modulated cardiovascular microbiota in vitro. Traditional use for circulatory disorders and hypertension is recognized by the German Federal Board of Health.

• beetScientific

  Beetroot exerts well-documented effects on the cardiovascular system via nitrate-derived NO, which lowers blood pressure, improves endothelial function, and reduces vascular resistance. Multiple RCT meta-analyses confirm clinically meaningful systolic BP reductions. Betanin additionally attenuates LDL oxidation and inflammatory atherogenic processes.

• belleric myrobalanScientific

  T. bellirica exerts multiple cardiovascular-relevant pharmacological effects including LDL oxidation inhibition, macrophage inflammation suppression (anti-atherogenic), cardioprotection against drug-induced injury, lipid profile improvement (cholesterol and triglyceride reduction), and antihypertensive effects in animal models. These properties collectively support a scientific basis for cardiovascular system engagement.

• benfotiamineScientific

  Benfotiamine protects the cardiovascular system by inhibiting NADPH oxidase, blocking PKC/NF-κB pathways, reducing AGE formation, and preserving endothelial function. Human RCTs have demonstrated prevention of smoking-induced endothelial dysfunction and acute AGE-meal-induced vascular impairment in diabetics. Animal data supports reduced infarct size and improved post-MI cardiac recovery.

• berberineScientific

  Berberine has substantial clinical and mechanistic evidence supporting its role in reducing cardiovascular disease (CVD) risk factors. Multiple randomized controlled trials and meta-analyses confirm significant reductions in LDL-C, total cholesterol, triglycerides, and systolic blood pressure. Evidence also exists for anti-arrhythmic and cardioprotective effects, though large-scale outcome trials are still lacking.

• bergamotScientific

  Bergamot (Citrus bergamia) polyphenols have been evaluated in multiple human clinical trials and systematic reviews for their lipid-lowering and broader cardiovascular effects. Evidence consistently shows reductions in total cholesterol, LDL-C, and triglycerides, with increases in HDL-C. The body of evidence is graded as scientific given the existence of randomized, double-blind, placebo-controlled trials in human populations, though study sizes remain relatively small and heterogeneity limits definitive conclusions.

• beta and delta tocopherolsScientific

  Delta and beta tocopherols, as components of mixed tocopherol preparations, protect cardiovascular function by inhibiting LDL oxidation, suppressing smooth muscle cell proliferation, reducing platelet aggregation, and lowering vascular inflammation. A human RCT confirmed that mixed tocopherols containing delta-tocopherol significantly reduced platelet aggregation, while alpha-tocopherol alone did not. Mixed tocopherol preparations are associated with reduced cardiovascular disease risk in observational studies.

• beta-alanineScientific

  The heart produces carnosine and related histidyl dipeptides at ~10 mM intracellular concentrations to buffer anaerobic acidosis and scavenge lipid peroxidation products. Carnosine levels are reduced in failing hearts, and preclinical evidence shows that BA supplementation can raise myocardial carnosine and protect against ischemia-reperfusion injury and adverse cardiac remodeling in heart failure models. Human evidence is currently preclinical/mechanistic; robust clinical RCT data in cardiac patients are not yet available.

• beta-glucanScientific

  Beta-glucan has extensive clinical evidence for cardiovascular benefit, primarily through LDL cholesterol reduction via bile acid sequestration, supported by FDA and EFSA health claims. Additional mechanisms include anti-inflammatory effects on arterial walls, improved gut microbiota (Akkermansia-mediated plaque reduction), and modest blood pressure reduction. It is among the most evidence-supported dietary ingredients for cardiovascular risk reduction.

• beta-sitosterolScientific

  Beta-sitosterol, the most abundant dietary phytosterol, has robust clinical evidence for lowering LDL cholesterol by competitively displacing cholesterol from intestinal micelles, reducing its absorption. Multiple human trials and meta-analyses document an average 10–15% reduction in LDL with supplemental doses. The U.S. FDA recognizes that diets including plant sterols such as beta-sitosterol may reduce the risk of coronary heart disease. Preclinical evidence also suggests additional cardioprotective mechanisms including anti-inflammatory and anti-atherosclerotic effects.

• betaineScientific

  Betaine (trimethylglycine) supports cardiovascular health primarily by lowering plasma homocysteine, an established cardiovascular risk factor, via the enzyme betaine-homocysteine methyltransferase (BHMT). Clinical meta-analyses confirm that supplemental doses of 4–6 g/day reduce plasma homocysteine by roughly 11–12% in healthy adults. A countervailing concern is that higher supplemental doses also modestly raise LDL and total cholesterol, which may partially offset the cardiovascular benefit. Prospective cohort data in coronary artery disease patients link higher dietary betaine intake to lower cardiovascular mortality.

• betelScientific

  Betel leaf exhibits antiplatelet aggregation activity, antihypercholesterolemic effects, and has been studied for cardioprotective potential in myocardial infarction models. Components such as eugenol and hydroxychavicol modulate lipid profiles and oxidative stress relevant to cardiovascular risk.

• bilberryScientific

  Bilberry anthocyanins exert direct protective effects on the cardiovascular system by improving endothelial function, inhibiting LDL oxidation, reducing platelet aggregation, lowering blood pressure, and improving capillary integrity. Clinical trials support benefits in post-AMI recovery, dyslipidemia, and blood pressure reduction in at-risk populations.

• black cuminScientific

  N. sativa has comprehensive clinical evidence for cardiovascular risk factor modification including blood pressure reduction, improvement of the full lipid profile (LDL, HDL, TG, TC), and reduction of inflammatory markers (CRP, IL-6, TNF-α, VCAM-1) across 82-RCT meta-analyses. These effects directly target major cardiovascular disease risk factors.

• black pepperScientific

  Piperine favorably modifies multiple cardiovascular risk parameters including LDL cholesterol, triglycerides, CRP, carotid intima-media thickness, and blood pressure in human RCTs. Mechanistically, it reduces intestinal cholesterol uptake, inhibits inflammatory mediators, and exhibits antihypertensive properties.

• black teaScientific

  Black tea exerts comprehensive benefits on the cardiovascular system including improved endothelial function, modest blood pressure and LDL reduction, and reduced platelet aggregation risk. These effects are demonstrated across multiple meta-analyses of RCTs and a Cochrane review. Theaflavins and thearubigins are the primary bioactive constituents.

• black walnutScientific

  Black walnut has documented, scientifically supported effects on the cardiovascular system: human dietary trials confirm reductions in LDL cholesterol, total cholesterol, and systolic blood pressure. High omega-3 ALA content, phytosterols, and polyphenols are the primary mechanistic drivers of cardiovascular protection.

• blackberryScientific

  Blackberry polyphenols support cardiovascular health through antioxidant protection of LDL, endothelial function improvement, lipid-level modulation, and anti-inflammatory effects on vascular tissues. Meta-analyses of RCTs on anthocyanin-rich berry consumption document significant reductions in total cholesterol and CRP. A nutrigenomic study validated blackberry's traditional use for hypertension by identifying vasodilatory bioactive molecules.

• blackboard treeScientific

  A. scholaris has been studied preclinically for cardioprotective, antihypertensive, and antihyperlipidemic effects. Vasorelaxation via calcium channel blockade and NO-mediated endothelium-dependent mechanisms has been confirmed in aortic ring preparations, and bark extracts are traditionally listed as cardiotonic in Ayurvedic medicine.

• bladderwrackScientific

  Bladderwrack's fucoidan demonstrates antithrombotic, ACE-inhibitory, and lipid-modifying effects. Clinical studies show reductions in LDL, triglycerides, and blood pressure with HDL increase. Epidemiological data link regular seaweed consumption to reduced ischemic heart disease.

• blueberryScientific

  Human RCTs and epidemiological studies demonstrate that blueberry anthocyanins improve endothelial function, modulate blood pressure, and reduce lipid and inflammatory risk factors for cardiovascular disease. Evidence is strongest for endothelial function and vascular health outcomes.

• borageScientific

  Borage seed oil GLA influences cardiovascular function through multiple documented pathways: reducing triglycerides, increasing HDL, and lowering blood pressure via prostaglandin E1-mediated vasodilation. Human clinical studies support triglyceride reduction and short-term blood pressure benefit, with a long-term study suggesting utility in correcting dyslipidaemia in at-risk patients.

• borage oilScientific

  GLA from borage oil exerts multiple favorable cardiovascular effects via DGLA and PGE1: vasodilation, antiplatelet activity, HDL elevation, LDL/triglyceride reduction, and blood pressure lowering. Clinical studies in postmenopausal hypertensive women, RA patients with dyslipidemia, and metabolic syndrome patients support cardiovascular benefit.

• bovine heartScientific

  Bovine heart delivers CoQ10, taurine, L-carnitine, and heme iron, all with documented cardiovascular-system evidence. CoQ10 is the most studied: a PMC 2021 review covering heart failure, hypertension, endothelial dysfunction, and cardiac surgery found it beneficial across multiple cardiovascular disease states at 200 mg/day doses.

• boxthorneScientific

  Boxthorn improves plasma lipidomic profiles, reduces oxidative stress and inflammation in heart failure models, and modulates LDL, HDL, and triglycerides in human RCTs. A 16-week human RCT confirmed lipidome alterations associated with cardiovascular protection in wolfberry consumers. TCM also used boxthorn against arteriosclerosis.

• brassicasterolScientific

  Brassicasterol, as a member of the phytosterol class, participates in the well-documented mechanism of intestinal cholesterol absorption inhibition, reducing circulating LDL-C and thereby influencing cardiovascular risk. Clinical guidelines from EFSA and the European Society of Cardiology formally endorse phytosterols for lipid management in cardiovascular disease prevention. Animal studies including brassicasterol-containing sterol mixtures show reduced atherosclerotic lesion burden.

• broccoliScientific

  Sulforaphane from broccoli protects vascular endothelium via Nrf2 activation, reducing oxidative stress, endothelial inflammation, and atherosclerotic signaling. Meta-analyses of clinical trials confirm significant blood pressure reduction and favorable lipid trends. Observational data associate higher cruciferous vegetable intake with reduced cardiovascular mortality.

• bromelainScientific

  Bromelain exerts multiple cardiovascular-relevant effects: it promotes fibrinolysis, inhibits platelet aggregation, reduces serum fibrinogen, and may break down cholesterol plaques. PMC reviews consistently identify cardiovascular disease as a primary area of bromelain's therapeutic application. Its antithrombotic and anticoagulant properties have been studied in heart patients and animal models of coagulation disorders.

• brown rice proteinScientific

  Brown rice protein and its phytochemicals (γ-oryzanol, subaleurone peptides, GABA) engage cardiovascular targets including angiotensin II inhibition, lipid lowering, and blood pressure reduction. Human data from a 3-month RCT (n=56 hyperlipidemic patients) show significant improvements in the full lipid panel. Meta-analyses link brown rice to reduced CVD risk factors including LDL-C, triglycerides, and CRP.

• brussel sproutsScientific

  Brussels sprouts supply potassium, folate, soluble fiber, glucosinolates, vitamin C, and plant omega-3s — a combination that supports blood pressure control, LDL reduction, endothelial function, and homocysteine management. Higher cruciferous vegetable intake is associated with reduced cardiovascular disease risk in epidemiological studies.

• butcher's broomScientific

  Butcher's broom has the strongest evidence base for its effects on the cardiovascular system, specifically venous tone and chronic venous insufficiency (CVI). Multiple RCTs and a meta-analysis of 20 placebo-controlled double-blind studies confirm reduction in CVI symptoms and leg edema. The German Commission E has approved it as adjunct CVI therapy.

• butyric acidScientific

  Butyrate influences multiple cardiovascular disease pathways including hypertension, atherosclerosis, and heart failure via GPCR activation, HDAC inhibition, and PPAR modulation. Clinical correlation between reduced gut butyrate-producing bacteria and hypertension has been documented in humans.

• cabbageScientific

  Cabbage provides anthocyanins, phytosterols, fiber, potassium, and vitamin C—compounds with established cardiovascular benefits. A 2024 RCT (VESSEL study) showed cruciferous vegetables (including cabbage) significantly reduced systolic blood pressure and triglycerides. Cabbage extract also protects cardiomyocytes from oxidative stress in vitro.

• cabbage leafScientific

  Human dietary intervention studies and observational data link regular cruciferous vegetable (including cabbage) consumption to improved cardiovascular risk markers. A 2-week human RCT (VESSEL study, PMC11367748) showed cruciferous vegetables lowered 24-hour systolic blood pressure vs. control vegetables. A human study of 38 volunteers consuming Brassica showed decreased LDL-cholesterol and oxidized LDL. Glucosinolates, antioxidants, and fiber are the primary proposed mechanisms.

• caesalpinia cristaScientific

  C. crista has demonstrated cardioprotective activity in isoproterenol-induced myocardial necrosis models in rats. Pretreatment with ethanolic and aqueous extracts at 400 mg/kg for 30 days significantly reduced elevated cardiac marker enzymes and protected against myocardial necrotic damage on histopathology.

• caffeineScientific

  Caffeine exerts well-documented acute effects on the cardiovascular system via adenosine receptor antagonism, increasing sympathetic tone, peripheral vascular resistance, and transiently raising blood pressure. It modifies cerebral and peripheral blood flow and affects myocardial blood flow response to exercise. Habitual use induces partial vascular adaptation.

• calamari oilScientific

  Calamari oil's DHA and EPA exert broad cardiovascular effects including triglyceride reduction, modest blood pressure lowering, heart rate reduction, antiplatelet activity, and anti-inflammatory endothelial effects. These mechanisms are supported by a large body of RCTs and meta-analyses. The FDA recognizes supportive evidence for EPA and DHA in coronary heart disease risk reduction.

• campesterolScientific

  Campesterol is clinically relevant to the cardiovascular system as a cholesterol absorption marker, an LDL-C lowering agent (as part of phytosterol supplementation), and a prognostic biomarker for cardiovascular events. Its plasma level reflects intestinal cholesterol absorption efficiency, which has bidirectional associations with cardiovascular risk in clinical studies.

• camu camuScientific

  Multiple human studies support camu camu's cardiovascular relevance: the 2008 RCT showed reduction of atherosclerosis-related oxidative and inflammatory markers; a 2017 human crossover study demonstrated vasodilation and blood pressure reduction after a single dose; and the 2024 RCT measured a full cardiovascular risk panel in overweight hypertriglyceridemic subjects.

• caprylic acidScientific

  Caprylic acid's cardiovascular relevance is established through lipid metabolism studies. Human RCT meta-analysis shows MCTs (C8/C10) produce a largely neutral lipid profile versus LCTs, without adverse LDL elevation. Animal studies show caprylic acid upregulates ABCA1 cholesterol efflux and reduces atherosclerotic inflammation via JAK2/STAT3 suppression.

• capsaicinoidsScientific

  Capsaicinoids activate TRPV1 receptors in endothelial cells and cardiac tissue, improving vascular tone, endothelial function, and cardiac protection from ischemia. Population studies associate spicy food consumption with reduced cardiovascular mortality. Effects include vasodilation, blood pressure reduction, cholesterol improvement, and anti-inflammatory vascular effects.

• capsanthinScientific

  Capsanthin benefits the cardiovascular system through inhibition of atherosclerotic plaque, reduction of vascular inflammation via NF-κB suppression, modulation of plasma lipids (raising HDL-C, lowering LDL-C and triglycerides), and antioxidant protection of vascular endothelium.

• capsicumScientific

  Capsaicin exerts multiple cardioprotective effects on the cardiovascular system including vasodilation via CGRP release, lipid lowering, modest blood pressure reduction, and anti-ischemic properties. RCT meta-analyses confirm measurable effects on cholesterol, LDL-C, and diastolic blood pressure.

• cardamomScientific

  Multiple RCTs and meta-analyses confirm cardamom's beneficial effects on cardiovascular risk parameters including blood pressure (significant diastolic reduction), triglycerides, total cholesterol, and inflammatory biomarkers (hs-CRP, IL-6, TNF-α). A 2024 meta-analysis of 12 RCTs (n=989) concluded cardamom consumption can improve specific cardiovascular metabolic biomarkers. Antioxidant and antithrombotic properties add further mechanistic support.

• carrotScientific

  Carrot phytochemicals—carotenoids, fiber, phenolics—exert cardioprotective effects through antioxidant, lipid-lowering, and blood-pressure-modulating mechanisms supported by epidemiological, animal, and limited human data. Regular carrot consumption is associated with reduced plasma lipids and blood pressure in multiple study models.

• caryophylleneScientific

  BCP has shown cardioprotective effects in diabetic cardiomyopathy, atherosclerosis, and vascular inflammation models. It reduces proatherogenic adhesion molecules, corrects eNOS/iNOS balance, and mitigates diet-induced vascular dysfunction via CB2 and PPAR-γ.

• caseinScientific

  Casein-derived bioactive peptides, particularly ACE-inhibitory lactotripeptides, directly support cardiovascular health through blood pressure reduction. Meta-analyses of milk protein supplementation show improvements in blood pressure, cholesterol, and triglycerides in metabolic disease populations. Casein phosphopeptides also support calcium homeostasis, which is relevant to vascular function.

• cassia barkScientific

  Cassia bark has direct relevance to the cardiovascular system through clinical and preclinical evidence for reductions in LDL cholesterol, triglycerides, blood glucose, and CRP—all major cardiovascular risk factors. Reviewed literature identifies cardiovascular protection as one of cassia/cinnamon's most consistent benefit areas.

• cat's clawScientific

  Cat's claw is documented to affect the cardiovascular system via hypotensive (blood pressure-lowering) and antiplatelet mechanisms. Preclinical studies show calcium-channel blocking by tetracyclic alkaloids and thrombin inhibition by bark extracts. Traditional use for hypertension and blood purification supports this association.

• catalaseScientific

  Catalase deficiency is associated with hypertension and diabetic cardiomyopathy through H₂O₂ accumulation and NF-κB-mediated cardiac injury. Mitochondria-targeted catalase protects against cardiac aging phenotypes in animal models. Acatalasemia is linked to elevated cardiovascular risk including dyslipidemia and hyperhomocysteinemia.

• catechinsScientific

  Catechins, particularly epigallocatechin gallate (EGCG), have substantial human and clinical evidence supporting cardiovascular benefits. These include reductions in systolic and diastolic blood pressure, improvements in flow-mediated dilation (FMD) as a marker of endothelial function, attenuation of atherosclerosis, and inhibition of platelet aggregation and thrombosis. Multiple systematic reviews and meta-analyses of randomised controlled trials confirm these associations, though effect sizes are modest and some methodological limitations remain.

• catjang cowpeaScientific

  Cowpea exerts multiple documented effects on cardiovascular risk factors: it reduces LDL cholesterol and apolipoprotein B in a human hypercholesterolemia trial, lowers triglycerides in animal studies, provides antioxidant polyphenols that inhibit LDL oxidation, and contains antihypertensive peptides. These collectively support a cardiovascular-protective role.

• cauliflowerScientific

  Cauliflower's sulforaphane, dietary fiber, potassium, and organosulfur compounds collectively protect the cardiovascular system through anti-inflammatory, antioxidant, lipid-lowering, and blood-pressure-modulating mechanisms. Epidemiological and intervention data support this relationship across the cruciferous vegetable class.

• cayenne pepperScientific

  Capsaicin exerts multiple cardiovascular effects including vasodilation, mild blood pressure reduction, cholesterol lowering, fibrinolytic activity enhancement, and anti-atherosclerotic actions—all mediated primarily through TRPV1 receptor signalling. Epidemiological data show regular chili pepper consumers have lower cardiovascular mortality.

• celeryScientific

  Celery's cardiovascular effects are among its most clinically validated actions. Multiple RCTs and a 2025 meta-analysis document significant reductions in blood pressure and triglycerides. Mechanistic pathways include vasodilation, calcium channel blockade, diuresis, and suppression of vascular inflammation.

• chaff flowerScientific

  A. aspera shows cardiovascular relevance through preclinical evidence of blood pressure lowering, cardiac stimulation via alkaloids and saponins, and lipid profile improvement. Traditional use for hypertension and as a cardiac tonic is consistent across multiple ethnomedical systems.

• chen piScientific

  Chen Pi acts on the cardiovascular system through lipid-lowering, anti-atherosclerotic, antihypertensive, and endothelial function-improving mechanisms. Clinical evidence from RCTs with its primary flavonoid hesperidin and preclinical data for nobiletin support a meaningful cardiovascular role.

• cherryScientific

  Human RCTs show tart cherry juice reduces systolic blood pressure, LDL cholesterol, CRP, and oxidized LDL in older adults. Subgroup meta-analyses confirm lipid improvements in unhealthy populations. Proposed mechanisms involve anthocyanin-mediated antioxidant and anti-inflammatory effects on vascular endothelium.

• chia seedScientific

  Chia seeds positively influence multiple cardiovascular risk factors: multiple RCT meta-analyses confirm reductions in SBP, LDL-C, total cholesterol, and triglycerides. ALA omega-3s, soluble fiber, and polyphenol antioxidants each contribute distinct cardioprotective mechanisms.

• chickpea proteinScientific

  Chickpea consumption reduces multiple cardiovascular risk factors including LDL-C, total cholesterol, and hsCRP in RCTs. ACE-inhibitory peptides from chickpea protein hydrolysates demonstrate blood-pressure-lowering effects in hypertensive animal models. The combined lipid, glucose, and inflammatory benefits map directly to reduced cardiovascular disease risk.

• chicoryScientific

  Chicory inulin-type fructans modulate multiple cardiovascular risk factors: they lower total cholesterol, LDL, and triglycerides in dyslipidemias, support healthy blood pressure in hypertensive patients, and reduce central adiposity. The prebiotic gut-liver axis mechanism (propionate-mediated) underlies lipid-lowering effects confirmed in RCT meta-analyses.

• chinese salvia rootScientific

  The cardiovascular system is Danshen's primary and most scientifically validated therapeutic domain. Over 39 clinical trials covering coronary heart disease, angina, heart failure, atherosclerosis, and arrhythmia establish this as the strongest evidence base. Compound Danshen preparations have FDA Phase II approval for CVD.

• chlorellaScientific

  Chlorella has been studied extensively in relation to cardiovascular risk markers. Meta-analyses of RCTs demonstrate improvements in cholesterol, LDL-C, blood pressure, and insulin sensitivity—all modifiable cardiovascular risk factors.

• chlorideScientific

  Serum chloride is an established prognostic marker in heart failure and cardiovascular disease. Hypochloremia independently predicts mortality in heart failure patients, outperforming serum sodium in several large trials. Chloride dysregulation is also implicated in myocardial electrical disturbances and arrhythmic risk.

• chokeberryScientific

  Chokeberry exerts multiple documented beneficial effects on the cardiovascular system in human clinical trials, including reductions in blood pressure, total and LDL cholesterol, platelet aggregation, and coagulation potential. Meta-analyses confirm systolic blood pressure and total cholesterol reduction. Combination with statin therapy showed enhanced cardiovascular risk factor reduction post-MI.

• chromic chlorideScientific

  Chromium has been reviewed for its potential role in cardiovascular health primarily through its effects on insulin resistance, glycemic control, and lipid profiles. A peer-reviewed review concludes chromium supplementation may help reduce insulin resistance and thereby reduce cardiovascular disease risk. Occupational epidemiological cohort data show no increased atherosclerotic heart disease in chromium compound workers exposed to trivalent chromium.

• chromiumScientific

  Chromium has clinical and mechanistic evidence for cardiovascular relevance primarily through its effects on insulin resistance, blood pressure, lipid metabolism, and inflammatory markers. A 2025 meta-analysis found chromium supplementation significantly decreases blood pressure in overweight/obese individuals. Proposed mechanisms include reduced angiotensin-converting enzyme activity and anti-inflammatory/antioxidant effects. Results are mixed across trials and no large cardiovascular outcome trials exist.

• chrysanthemumScientific

  Chrysanthemum flavonoids and terpenes exert vasodilatory, antihypertensive, lipid-lowering, and anti-atherosclerotic effects in preclinical models. The herb is listed in traditional medicine for hypertension and angina. Preclinical studies show blood pressure reduction, cardiac hypertrophy reversal, and cholesterol normalization.

• chrysinScientific

  Chrysin exerts multiple cardioprotective effects via antioxidant, anti-inflammatory, and hypolipidemic mechanisms. It protects against ischemia-reperfusion injury, reduces atherosclerotic risk factors, inhibits platelet activation, lowers LDL-C and triglycerides, and modulates endothelial nitric oxide bioavailability. All evidence is preclinical.

• cinnamonScientific

  Cinnamon modulates multiple cardiovascular risk factors simultaneously—blood pressure, LDL/total cholesterol, triglycerides, blood glucose, and systemic inflammation. A 2025 GRADE meta-analysis of 49 RCTs confirmed broad significant improvements across cardiovascular risk biomarkers. Mechanisms include HMG-CoA reductase inhibition, vasodilation, and NF-κB suppression.

• cissus quadrangularisScientific

  Human RCTs have documented simultaneous reductions in total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein, and fasting blood glucose in participants taking CQ extract, collectively lowering multiple established cardiovascular risk factors. The 2007 RCT also showed in vivo antioxidant activity reducing plasma TBARS and carbonyls, markers of oxidative damage implicated in atherogenesis.

• citrus pectinScientific

  Citrus pectin exerts well-documented cardiovascular effects via LDL-cholesterol reduction through bile acid sequestration. Modified citrus pectin additionally targets galectin-3, a biomarker of cardiovascular disease, fibrosis, and heart failure. Multiple human clinical trials confirm lipid-lowering effects; preclinical models show anti-fibrotic and anti-atherogenic actions.

• citrus sinensisScientific

  C. sinensis hesperidin and flavanones have demonstrated broad cardiovascular benefits in multiple RCTs: improved endothelial function, reduced blood pressure, lower LDL and total cholesterol, reduced triglycerides, and decreased vascular inflammatory markers. A 2024 meta-analysis of 12 RCTs confirmed effects on multiple CVD risk factors.

• CLA (conjugated linoleic acid)Scientific

  CLA influences multiple cardiovascular system parameters. Clinical evidence confirms it reduces body fat and BMI in CVD-risk patients and lowers the vascular adhesion marker ICAM-1. Its effects on lipid profiles and blood pressure are inconsistent across meta-analyses, and higher doses may adversely reduce HDL.

• cocoaScientific

  Cocoa flavanols comprehensively support cardiovascular health through improved endothelial function (FMD), blood pressure reduction, antiplatelet activity, LDL oxidation resistance, and anti-inflammatory effects. The COSMOS trial demonstrated a 27% reduction in CVD mortality with 500 mg/day flavanols over 3.6 years.

• coconutScientific

  Clinical trial evidence consistently demonstrates coconut oil raises both LDL-C (atherogenic) and HDL-C (protective), with a net cardiovascular risk profile considered unfavorable by major health bodies versus unsaturated fats. VCO specifically may modestly reduce triglycerides. The cardiovascular evidence base is among the most extensively studied for coconut oil.

• coconut milkScientific

  Coconut milk's MCFAs modulate cardiovascular biomarkers, consistently raising HDL cholesterol and showing neutral-to-favorable LDL effects versus butter in RCTs. Its polyphenols reduce CRP and inhibit inflammatory pathways relevant to atherosclerosis. Evidence is mixed at the population level, with some epidemiological data suggesting elevated vascular risk with high coconut milk intake.

• coconut oilScientific

  Coconut oil has a well-characterized and contested effect on cardiovascular risk factors. RCT meta-analyses confirm it raises LDL-C (a cardiovascular risk factor) but also raises HDL-C relative to nontropical vegetable oils. It does not significantly affect glycemia, blood pressure, or CRP. The AHA recommends limiting coconut oil due to its LDL-raising effects.

• cod liver oilScientific

  Cod liver oil EPA and DHA exert multiple favorable effects on the cardiovascular system: lowering triglycerides, modestly raising HDL, reducing platelet aggregation, and anti-inflammatory vascular actions. A large interventional study in 870 at-risk patients found fewer myocardial infarction events with CLO supplementation.

• coenzyme AScientific

  Coenzyme A (CoA) is an essential intracellular cofactor whose homeostasis is directly linked to cardiac function. Accumulating evidence from biochemical studies, inherited metabolic disease case series, and preclinical experiments demonstrates that CoA limitation is a critical driver of cardiac dysfunction. Defects in CoA biosynthesis enzymes in humans present predominantly as dilated cardiomyopathy and heart failure, and restoring CoA levels via pantethine therapy has rescued end-stage cardiac failure in a clinical case report. CoA's role in fatty acid oxidation, the citric acid cycle, and cardiac energy metabolism underpins this cardiovascular relevance.

• coffee fruitScientific

  Coffee fruit's chlorogenic acids improve vascular endothelial function, reduce systolic blood pressure, lower triglycerides, and improve HDL. Human RCTs have demonstrated significant reductions in SBP (−5.56 mmHg, p=0.01), significant TG reductions, and improved vasoreactivity with CGA-standardized extracts sharing coffee fruit's phytochemistry. CGA also prevents LDL oxidation, a key atherogenic process.

• coixScientific

  Coix seed extract has demonstrated cardiovascular-relevant effects in animal studies including reductions in total cholesterol, LDL-C, and triglycerides, increases in HDL-C, inhibition of liver cholesterol synthesis, anti-inflammatory effects on endothelium, and anti-hypertensive properties.

• coleus forskohliiScientific

  Forskolin from Coleus forskohlii acts on the cardiovascular system through multiple cAMP-mediated mechanisms: positive inotropy in myocardial tissue, vasodilation via smooth muscle relaxation, blood pressure reduction, and antiplatelet aggregation. Clinical trials have tested IV forskolin in heart failure, and human tissue studies confirm myocardial adenylate cyclase activation.

• collagenScientific

  A 2022 systematic review and meta-analysis in the British Journal of Nutrition (12 RCTs) found collagen peptide supplementation significantly decreased systolic blood pressure (–5.04 mmHg) and serum LDL cholesterol. Proposed mechanisms include ACE-inhibitory activity, activation of nitric oxide-mediated vasodilation, and reduction of arterial stiffness. Collagen type I and III are primary structural components of arterial walls, making their turnover relevant to vascular health.

• collardScientific

  Collard greens support the cardiovascular system via soluble fiber (lowers LDL), potassium (lowers blood pressure), folate (reduces homocysteine), vitamin K (inhibits arterial calcification), and glucosinolate-derived isothiocyanates (anti-inflammatory, endothelial-protective). Epidemiological evidence links green leafy vegetable intake to significantly reduced cardiovascular disease risk.

• commiphoraScientific

  Commiphora mukul guggulsterones have been studied in human RCTs for effects on serum lipids, lipid peroxidation, and platelet aggregation — all cardiovascular risk factors. Clinical evidence is mixed for lipid lowering but positive for antioxidant effects relevant to cardiovascular protection.

• copperScientific

  Copper supports cardiovascular structure and function through lysyl oxidase-mediated collagen/elastin cross-linking in vessels, ceruloplasmin-regulated iron and HDL metabolism, VEGF-driven myocardial angiogenesis, and mitochondrial energy production in cardiomyocytes. Epidemiological studies associate dietary copper intake with cardiovascular disease risk and outcomes.

• coptis chinensisScientific

  Berberine from Coptis chinensis exerts multiple cardiovascular actions including lipid lowering, anti-arrhythmic effects, antihypertensive activity, and anti-atherosclerotic effects. These are documented in pharmacological reviews, animal studies, and clinical lipid trials.

• CoQ10 (coenzyme Q10)Scientific

  CoQ10 has robust clinical evidence supporting its role in cardiovascular health, particularly in heart failure (HF). It functions as a critical electron carrier in mitochondrial energy production and as a potent antioxidant, both of which are compromised in failing hearts. The landmark Q-SYMBIO RCT (420 patients, 2 years) demonstrated significant reductions in major adverse cardiovascular events, cardiovascular mortality, and hospitalizations at 300 mg/day. Multiple systematic reviews also support its adjunctive use in hypertension, ischemic heart disease, and endothelial dysfunction.

• cordycepsScientific

  Cordyceps exerts documented effects across multiple components of the cardiovascular system, including the heart, vasculature, and blood lipids. Clinical evidence from meta-analyses of arrhythmia RCTs and preclinical data on atherosclerosis, thrombosis, and hypertension support a broad cardiovascular role. Cardioprotective mechanisms involve adenosine signaling, NO-mediated vasodilation, antioxidant activity, and anti-inflammatory effects.

• cornScientific

  Corn silk has RCT-based evidence for blood pressure reduction (5 RCTs, n=567) and lipid improvement in angina patients (4 RCTs). Its antioxidant and anti-inflammatory bioactives support cardiovascular protection in preclinical models. The cardiovascular evidence base is the most developed in clinical terms.

• cornsilkScientific

  Corn silk demonstrates cardiovascular effects through confirmed antihypertensive activity (meta-analysis of 5 RCTs), hypolipidemic effects in animal studies, and in vitro inhibition of endothelial cell adhesion molecule expression relevant to atherosclerosis. Its diuretic, anti-inflammatory, and antioxidant properties collectively support cardiovascular system health.

• cottonseed oilScientific

  CSO's effects on the cardiovascular system are the most extensively clinically studied area. Multiple RCTs demonstrate improvements in lipid profiles (LDL-C, total cholesterol, triglycerides), inflammatory markers (TNF-α, tissue factor), and postprandial glycemia in healthy and hypercholesterolemic adults. These surrogate endpoint improvements mechanistically support reduced CVD risk.

• cranberryScientific

  Clinical evidence from RCTs demonstrates that cranberry polyphenols improve multiple cardiovascular parameters including endothelial function, arterial stiffness, CRP, and triglycerides. The cardiovascular system effects operate through polyphenol-mediated improvements in vascular tone, lipid oxidation, and systemic inflammation. Evidence is most consistent for endothelial function; effects on lipid panels remain mixed.

• creatineScientific

  Creatine supplementation has demonstrated effects on vascular parameters including arterial stiffness reduction in older adults, and the phosphocreatine/creatine kinase system is fundamental to cardiac energy metabolism. Cardiac creatine depletion is a hallmark of heart failure, and preliminary clinical evidence supports creatine's potential role in cardiovascular disease management.

• creatine monohydrateScientific

  Creatine monohydrate supports cardiovascular function through its role in cardiac energy metabolism, antioxidant properties, and potential effects on microvascular blood flow and vascular inflammation. Evidence spans mechanistic reviews, pilot RCTs, and established cardiac biochemistry research.

• cryptoxanthinScientific

  BCX reduces LDL oxidation, suppresses NF-κB-driven vascular inflammation, and lowers cardiometabolic risk markers in animal studies. Higher BCX intake or serum levels are inversely associated with cardiovascular disease and mortality in multiple observational studies in humans.

• cucumberScientific

  Cucumber's potassium, magnesium, and plant sterols support cardiovascular health by reducing blood pressure, promoting vasodilation, and modulating the lipid profile. Animal and limited human evidence confirms anti-hypertensive and lipid-lowering effects. IdoBR1-mediated reduction of TNF-α also addresses inflammatory components of cardiovascular risk.

• cuminScientific

  Cumin has been shown in RCTs and meta-analyses to favorably modify cardiovascular risk markers: reducing LDL, total cholesterol, triglycerides, oxidized LDL, and raising HDL. Its antioxidant compounds protect vascular endothelium. No direct evidence for reduction of cardiovascular events exists.

• curcuminScientific

  Curcumin, the primary polyphenol in turmeric (Curcuma longa), has been investigated in multiple human randomized controlled trials and meta-analyses for cardiovascular benefits. Clinical evidence supports modest improvements in endothelial function, blood pressure, and lipid profiles, primarily through anti-inflammatory and antioxidant mechanisms. Results across trials are inconsistent, partly due to curcumin's inherently poor oral bioavailability, variable formulations, and heterogeneous study populations. The overall body of evidence is promising but characterized as preliminary, requiring larger, well-standardized trials to confirm clinical utility.

• currantScientific

  Blackcurrant anthocyanins benefit cardiovascular function through improved endothelial function (FMD), reduced platelet aggregation, anti-inflammatory effects, lipid profile improvement, and blood pressure modulation. Human RCTs and prospective cohort data consistently support cardiovascular risk reduction with anthocyanin-rich berry intake.

• d-alpha tocopherolScientific

  D-alpha tocopherol exerts multiple cardioprotective mechanisms including LDL oxidation inhibition, platelet aggregation suppression, endothelial function improvement, and anti-inflammatory activity. However, large RCTs have not translated these mechanistic benefits into consistent reductions in cardiovascular events in the general population.

• D-glucarateScientific

  D-glucarate has preliminary evidence for cardiovascular relevance through two pathways: lipid lowering (reductions in LDL and total cholesterol) and antioxidant/antiplatelet activity in human platelet models. These mechanisms are relevant to atherosclerosis and thrombosis risk but have not been tested in cardiovascular outcome trials.

• D-riboseScientific

  D-ribose acts as a rate-limiting substrate for myocardial ATP synthesis and has been clinically evaluated in ischemic cardiovascular disease and congestive heart failure. Multiple peer-reviewed human trials demonstrate improved diastolic function, increased ischemic threshold, and enhanced exercise tolerance. Evidence is strongest for ischemic and failing hearts.

• daidzinScientific

  Daidzin and daidzein exert multiple cardiovascular effects in preclinical models including anti-hyperlipidemic, antihypertensive, antithrombotic, and anti-inflammatory actions. Clinical data confirm modest anti-hyperlipidemic effects. Cross-sectional human data link efficient daidzin metabolism to better cardiovascular risk profiles.

• dandelionScientific

  Dandelion acts on the cardiovascular system through confirmed diuretic effects (human pilot study, n=17), preclinical antihypertensive, antiplatelet, hypolipidemic, and anti-atherosclerotic activities. Its polyphenol content supports vascular protection via antioxidant and anti-inflammatory mechanisms across multiple animal models.

• delta-tocopherolScientific

  Delta-tocopherol contributes to cardiovascular health by inhibiting smooth muscle cell proliferation, reducing LDL oxidation, suppressing vascular endothelial inflammation, and inhibiting platelet aggregation—all mechanistically relevant to atherosclerosis prevention. Mixed tocopherol preparations containing δ-tocopherol show better anti-inflammatory and antioxidant vascular actions than α-tocopherol alone. Epidemiological evidence supports inverse associations between vitamin E intake and cardiovascular disease, though α-tocopherol-only RCTs have been negative.

• devil's clawScientific

  Devil's Claw exerts documented pharmacological effects on the cardiovascular system, including dose-dependent reductions in blood pressure and heart rate in animal models. A peer-reviewed case report documented symptomatic hypertension in a human user. NCCIH, clinical pharmacology databases, and the EMA caution about cardiovascular effects.

• DHA (docosahexaenoic acid)Scientific

  DHA (Docosahexaenoic Acid) has robust clinical and epidemiological evidence supporting its role in cardiovascular health, primarily through lowering triglycerides, reducing blood pressure, improving HDL cholesterol, inhibiting platelet aggregation, and modulating vascular inflammation. Large meta-analyses of randomized controlled trials link omega-3 supplementation (EPA+DHA) to significant reductions in cardiovascular mortality, non-fatal myocardial infarction, and major adverse cardiovascular events. DHA appears to have a particularly strong triglyceride-lowering effect compared to EPA alone, though high-dose supplementation is associated with increased atrial fibrillation risk.

• diamine oxidaseScientific

  DAO deficiency allows excess histamine to reach the cardiovascular system, where it causes hypotension, tachycardia, and arrhythmias via H1 and H2 receptor stimulation on vascular smooth muscle and cardiac tissue. Clinical trials of DAO supplementation demonstrate significant reductions in cardiovascular symptom scores in histamine intolerance patients. Case series document cardiovascular presentations of DAO deficiency misdiagnosed as anxiety or panic.

• dioscoreaScientific

  Dioscorea constituents have demonstrated lipid-lowering, anti-atherosclerotic, cardioprotective, and estrogen receptor-mediated effects in preclinical models. Dioscin attenuates postmenopausal atherosclerosis and myocardial dysfunction in animal models. Human evidence is limited to dietary observational data.

• diosminScientific

  Diosmin is a flavone glycoside with well-documented clinical evidence for supporting the cardiovascular system, particularly in the treatment of chronic venous insufficiency (CVI) and chronic venous disease (CVD). It acts as a venoactive (phlebotropic) agent that improves venous tone, reduces capillary permeability, enhances lymphatic drainage, and exerts anti-inflammatory and antioxidant effects on the vascular endothelium. Multiple randomized controlled trials and a 2020 Cochrane meta-analysis of 56 trials support its efficacy in reducing edema, pain, and venous symptoms. Preclinical data also suggest antihypertensive and cardioprotective properties via modulation of the renin-angiotensin system and endothelial function.

• docosahexaenoic acidScientific

  DHA is one of the most extensively studied nutrients for the cardiovascular system, with effects on triglycerides, HDL cholesterol, blood pressure, heart rate, platelet function, endothelial function, and atherosclerosis. Multiple systematic reviews of RCTs confirm these cardiovascular risk factor improvements. DHA modulates lipid metabolism, inflammation, ion channels, and autonomic function via vagal tone.

• dodderScientific

  Cuscuta chinensis extracts are documented to protect cardiovascular function through antioxidant, anti-inflammatory, and vasodilatory mechanisms. Classical pharmacology shows lowering of blood pressure in anesthetized animals and positive inotropic effects. The flavonoid profile (quercetin, kaempferol) is directly relevant to endothelial health and vascular function. Antihypertensive and cardioprotective activities are classified as statistically significant in the pharmacological literature.

• dog roseScientific

  Rosa canina preparations have demonstrated measurable effects on multiple cardiovascular risk markers in human clinical trials, including reduced LDL cholesterol, lowered systolic blood pressure, reduced visceral fat, and improved cardiovascular risk scores. Antioxidant protection of vascular endothelium is also mechanistically documented.

• dogwoodScientific

  Cornus officinalis has documented preclinical cardiovascular protective effects including cardioprotection in myocardial infarction models, antihypertensive potential, antiarrhythmic activity, and mitochondrial protection in heart failure models. Multiple PMC reviews identify cardiovascular protection as a primary pharmacological effect.

• dong quaiScientific

  Dong Quai and its constituents have multiple documented cardiovascular pharmacological actions: vasodilation (ligustilide via calcium channel inhibition), antithrombotic effects (ferulic acid/coumarin), anti-atherosclerotic effects (17 chemical components targeting 26 drug targets), cardioprotection against myocardial infarction and fibrosis, and antiarrhythmic activity. TCM has applied the herb to cardiovascular conditions for over 2,000 years.

• DPA (docosapentaenoic acid)Scientific

  DPA exerts multiple cardiovascular protective actions: it inhibits platelet aggregation more potently than EPA or DHA, stimulates endothelial cell migration for vascular repair, reduces inflammatory gene expression in arterial walls, and is inversely associated with fatal coronary heart disease risk in large prospective cohort analyses. It also favorably modulates triglycerides and contributes to anti-thrombotic eicosanoid profiles.

• dulse leafScientific

  Dulse protein hydrolysates yield ACE-inhibitory peptides (including LRY with IC50 0.044 µmol) that are mechanistically relevant to blood pressure regulation within the cardiovascular system. Dulse's potassium content supports vasodilation. Omega-3 fatty acids and polyphenols in dulse have documented anti-inflammatory effects relevant to vascular health.

• EGCG (epigallocatechin gallate)Scientific

  EGCG (epigallocatechin gallate), the principal catechin in green tea, has human clinical and systematic-review evidence supporting cardiovascular benefits including LDL-cholesterol reduction, blood pressure lowering, and improved endothelial function. A systematic review of 17 RCTs found 107–856 mg/day for 4–14 weeks significantly reduced LDL-C by ~9.3 mg/dL. A randomized crossover trial showed a single 300 mg dose acutely improved brachial artery flow-mediated dilation in coronary artery disease patients. Overall evidence is promising but remains in need of larger, longer clinical trials.

• eggScientific

  Egg consumption and cardiovascular outcomes has been studied in numerous prospective cohorts and RCTs. Evidence is mixed: moderate intake (≤1/day) appears safe for most healthy adults, with potential benefits on HDL function and lipoprotein profiles, but high intake or dietary cholesterol burden is associated with modest CVD risk increases in some pooled analyses.

• eicosapentaenoic acidScientific

  EPA exerts comprehensive cardioprotective effects: lowering triglycerides, inhibiting platelet aggregation, improving endothelial function, reducing arterial inflammation, and stabilizing atherosclerotic plaques. Landmark RCTs (REDUCE-IT, JELIS) established 19–25% reductions in major adverse cardiovascular events with EPA supplementation.

• eicosenoic acidScientific

  Animal model evidence shows that eicosenoic acid-rich marine oil diets reduce cardiovascular disease risk factors and suppress atherosclerotic processes including lipid deposition in vessel walls. LCMUFA fractions containing eicosenoic acid have been shown to improve plasma lipid profiles and reduce macrophage accumulation in vascular tissue in rodents. No human trials with isolated eicosenoic acid in cardiovascular end-points have been completed.

• eleutheroScientific

  Human supplementation studies show eleuthero can lower blood pressure, reduce arterial stiffness, and improve endothelial function via eNOS upregulation. Animal studies demonstrate reduction in atherosclerotic lesions. Traditional use includes treatment of hypertension, ischemic disorders, and cardiovascular inflammation.

• enicostemma littoraleScientific

  E. littorale has demonstrated cardioprotective activity in an isoproterenol-induced cardiac hypertrophy rat model, normalizing lipid profiles and cardiac enzyme levels more efficiently than losartan. Human data show reductions in blood pressure and pulse rate. Swertiamarin is identified as a cardioprotective and antiatherosclerotic compound compared to atorvastatin.

• EPA (eicosapentaenoic acid)Scientific

  EPA (eicosapentaenoic acid) has robust clinical and mechanistic evidence supporting cardiovascular benefit. It lowers triglycerides, reduces systemic inflammation, stabilizes atherosclerotic plaques, and improves endothelial function. The landmark REDUCE-IT RCT (n=8,179) demonstrated a ~25% reduction in major adverse cardiovascular events with high-dose EPA (4 g/day) in statin-treated, high-risk patients. High-dose EPA supplementation may also carry an increased risk of atrial fibrillation.

• eucommiaScientific

  Eucommia has multi-level cardiovascular system activity: antihypertensive (clinical RCT evidence), anti-atherosclerotic (animal models), lipid-lowering (preclinical), and vascular endothelium-protective (human FMD data). Lignan and iridoid compounds mediate these effects via NO signaling, renin-angiotensin modulation, and anti-inflammatory pathways.

• evening primrose oilScientific

  EPO influences the cardiovascular system through its GLA content, which modulates prostaglandin E1 production (vasodilatory, anti-platelet), affects lipid profiles (lowers LDL and TG, raises HDL), and reduces inflammatory eicosanoids implicated in atherosclerosis. Clinical evidence is limited to surrogate marker improvements rather than hard cardiovascular outcomes.

• fava beanScientific

  Fava beans beneficially influence the cardiovascular system through soluble fiber (reduces LDL cholesterol), potassium and magnesium (regulate blood pressure), folate (reduces homocysteine), polyphenols (antioxidant endothelial protection), and L-DOPA (stimulates nitric oxide production). Epidemiological and clinical data support cardiovascular risk reduction with regular legume consumption.

• fennelScientific

  Foeniculum vulgare demonstrates antihypertensive, vasorelaxant, hypolipidemic, antiplatelet, antioxidant, and anticoagulant effects in preclinical research. A 2025 comprehensive review synthesized these cardiovascular pharmacological properties. Human clinical evidence is not yet established.

• fenugreekScientific

  Fenugreek exerts multiple beneficial effects on the cardiovascular system: reducing LDL-C, total cholesterol, and triglycerides while raising HDL-C; modestly lowering diastolic blood pressure; and providing antioxidant protection of vascular endothelium. These effects are supported by meta-analyses of RCTs in diabetic and metabolic syndrome populations.

• ferula assafoetidaScientific

  Asafoetida exerts multiple cardiovascular effects: it lowers blood pressure via smooth-muscle relaxation, reduces cholesterol and triglycerides in animal models, inhibits platelet aggregation via coumarin constituents, and suppresses vascular inflammation (TNF-α, VCAM-1, ICAM-1) in endothelial cell studies. Ferulic acid RCTs in humans confirm lipid and inflammatory marker reduction.

• ferulic acidScientific

  Ferulic acid improves cardiovascular function through antioxidant, anti-inflammatory, lipid-lowering, antihypertensive, and anti-platelet mechanisms. An RCT in hyperlipidemic humans demonstrated significant improvements in all major CVD risk markers with 1 g/day FA × 6 weeks. Sodium ferulate has traditional use in Chinese medicine for cardiovascular and cerebrovascular disease.

• feverfewScientific

  Parthenolide inhibits platelet aggregation and serotonin release from platelets, reducing thrombotic and vasoconstrictive signaling. These effects have been documented in in vitro and ex vivo studies and are considered relevant to feverfew's anti-migraine mechanism. NCCIH notes the herb may slow blood clotting.

• fisetinScientific

  Fisetin protects the cardiovascular system through anti-inflammatory, antioxidant, anti-fibrotic, and endothelial senolytic mechanisms in multiple rodent models. It reduces dyslipidemia, cardiac fibrosis, endothelial dysfunction, and metabolic-stress cardiac injury.

• fish oilScientific

  Fish oil, rich in the omega-3 fatty acids EPA and DHA, has extensive clinical and epidemiological evidence supporting cardiovascular benefit, particularly for secondary prevention. Established mechanisms include triglyceride reduction, antiarrhythmic effects, blood pressure lowering, anti-inflammatory action, and platelet aggregation inhibition. Evidence is strongest for high-dose EPA in high-risk patients, while results at lower doses in primary prevention are inconsistent across trials.

• flavin mononucleotideScientific

  FMN and FAD mediate cardiovascular health through MTHFR-dependent homocysteine metabolism, nitric oxide synthase function, and endothelial redox balance. RCTs demonstrate that riboflavin (FMN/FAD precursor) lowers both homocysteine and blood pressure specifically in MTHFR 677TT individuals, two recognized cardiovascular risk factors.

• flaxseedScientific

  Flaxseed exerts multiple documented favorable effects on the cardiovascular system: lowering LDL cholesterol, reducing blood pressure, inhibiting arrhythmias in animal models, reducing atherosclerosis risk, and lowering inflammatory markers. A 2018 American Journal of Physiology review comprehensively documented these cardiovascular benefits.

• flowering quinceScientific

  C. speciosa supplementation reduced LDL cholesterol, total cholesterol, and atherosclerotic plaque area in mouse models. Its antioxidant compounds protect lipids from oxidation, and ursolic and oleanolic acids in the fruit have established cardioprotective properties. No human cardiovascular trials exist.

• folic acidScientific

  Folic acid is extensively studied for cardiovascular protection, primarily through its role as a key cofactor in homocysteine metabolism. Clinical evidence shows a consistent, modest benefit for stroke prevention—particularly in populations without mandatory folic acid food fortification and those with elevated homocysteine—but no significant reduction in broader cardiovascular events such as myocardial infarction or cardiovascular mortality. The evidence is mixed and context-dependent, with guidelines treating folic acid as a secondary rather than primary cardiovascular intervention.

• folinic acidScientific

  Folinic acid reduces plasma homocysteine—an independent cardiovascular risk factor—in clinical trials of hemodialysis patients. Intravenous folinic acid has additionally been shown to reduce lipid peroxidation markers, potentially attenuating atherosclerosis risk. The homocysteine-lowering effect of folinic acid is comparable to folic acid at equimolar doses.

• forskohlii rootScientific

  Forskolin exerts multiple cardiovascular effects: vasodilation via vascular smooth muscle cAMP elevation, positive inotropy in cardiac muscle, blood pressure reduction, and platelet aggregation inhibition. Clinical evidence exists from IV administration in heart failure and intraoperative settings.

• forsythiaScientific

  Forsythiasides from Forsythia suspensa have documented cardiovascular protective effects in preclinical research, with a dedicated 2022 Frontiers in Cardiovascular Medicine review. Forsythoside A's antioxidant and anti-inflammatory properties are relevant to vascular health, and Forsythia is traditionally described as a cardiovascular tonic. Preclinical evidence predominates; human trials are lacking.

• FOS (fructooligosaccharides)Scientific

  FOS may modestly benefit cardiovascular risk factors — particularly total cholesterol and triglycerides in diabetic populations — through SCFA-mediated inhibition of hepatic lipogenesis. Human RCT data show significant benefits in diabetics but not consistently in general or hyperlipidemic populations. Anti-inflammatory SCFA effects further support cardiovascular relevance.

• fulvic acidScientific

  Human cardiovascular shilajit trials report improvements in oxidized LDL, arterial flexibility, and endogenous antioxidants. Fulvic acid's CoQ10-stabilizing and nitric oxide-supporting properties mechanistically benefit cardiac energy and vascular function. Anti-inflammatory effects reduce cardiovascular inflammatory drivers.

• fungal proteaseScientific

  Aspergillus-derived fungal proteases have demonstrated fibrinolytic, anticoagulant, and plasminogen-activating properties in vitro and in early human studies. A 30-day clinical trial in active men found that fungal protease co-supplementation with whey protein did not adversely affect cardiovascular markers and was associated with an improved lipid profile versus whey alone.

• gamma oryzanolScientific

  Gamma oryzanol benefits the cardiovascular system through lipid lowering, endothelial protection, anti-inflammatory activity at the vascular wall, and protection against cardiac structural changes in metabolic disease. It is approved in Japan for cardiovascular-related lipid management.

• gamma tocopherolScientific

  Gamma-tocopherol exerts multiple cardiovascular-relevant actions: inhibiting LDL oxidation, reducing platelet aggregation, suppressing neointimal arterial proliferation, and reducing systemic oxidative-nitrosative stress. Plasma γT is selectively depressed in coronary artery disease patients. Human cohort data on cardiovascular mortality show mixed results depending on population and methodology.

• ganodermaScientific

  Ganoderma lucidum affects the cardiovascular system through multiple mechanisms including ACE inhibition, anti-platelet activity, antioxidant protection, and direct cardioprotective effects demonstrated in animal models. Human RCT data show modest effects on heart rate but not consistently on blood pressure or lipids.

• garbanzo beanScientific

  Garbanzo beans exert multiple protective effects on the cardiovascular system: soluble fiber reduces LDL cholesterol and triglycerides, potassium and magnesium moderate blood pressure, folate lowers homocysteine, and polyphenols inhibit LDL oxidation and vascular inflammation. Meta-analyses of legume consumption including chickpeas consistently demonstrate reduced cardiometabolic risk factors.

• gardeniaScientific

  Gardenia jasminoides and its constituents (geniposide, genipin, crocin) exert multiple cardiovascular-relevant effects including blood pressure reduction, antithrombotic/antiplatelet activity, cholesterol and triglyceride lowering, and endothelial cell protection. These effects have been documented in animal cardiovascular models and are the subject of a dedicated pharmacological review.

• gardenia jasminoidesScientific

  Gardenia jasminoides has demonstrated multiple cardiovascular-relevant effects in preclinical models: antihypertensive effects via geniposide-mediated eNOS/nNOS upregulation, cardioprotection against myocardial injury, antithrombotic/antiplatelet activity, and hypolipidemic effects. Traditional TCM use includes heart meridian action. Comprehensive cardiovascular pharmacology has been reviewed in PubMed-indexed literature.

• garlicScientific

  Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) confirm that garlic supplementation produces modest but statistically significant reductions in blood pressure, total cholesterol, LDL cholesterol, and triglycerides, particularly in adults with elevated baseline risk. The NIH/NCCIH acknowledges this body of evidence while characterizing the effects as small. Mechanistically, garlic's primary bioactive compound, allicin, exerts antihypertensive, hypolipidemic, antiplatelet, and antioxidant effects. Traditional use across ancient Mediterranean, Asian, and Middle Eastern cultures mirrors these cardiovascular applications, predating modern clinical study.

• garlic bulbScientific

  Garlic exerts well-documented beneficial effects across multiple cardiovascular system parameters: blood pressure, blood lipids, platelet aggregation, arterial stiffness, and endothelial function. Meta-analyses of RCTs confirm statistically significant effects on each domain, establishing garlic as one of the most clinically studied herbal supplements for cardiovascular health.

• gastrodiaScientific

  Gastrodin has been extensively used in China for cardiovascular and cerebrovascular diseases. It reduces blood pressure via RAAS inhibition, promotes vasodilation through potassium channel activation, and has been studied in hypertensive cardiac models showing protection against myocardial apoptosis.

• genisteinScientific

  Genistein exerts documented favorable effects throughout the cardiovascular system, including endothelial function, lipid profiles, blood pressure, homocysteine levels, and cardiac function. Multiple systematic reviews and meta-analyses of RCTs confirm these effects. Both estrogenic and non-estrogenic mechanisms are operative.

• gentianScientific

  A systematic review of Gentiana lutea (53 publications) documented anti-atherosclerotic activity mediated by AMPK and eNOS signalling and inhibition of smooth muscle cell proliferation and migration. G. lutea extracts protected human vascular endothelial cells from cigarette smoke damage in vitro. Isogentisin promotes vascular cell survival via cellular repair mechanisms. Evidence is preclinical only.

• geraniumScientific

  Clinical trials show that geranium aromatherapy reduces blood pressure and heart rate in surgical patients. A triple-blind RCT confirmed cardiovascular physiological effects including reduced heart rate in patients with myocardial infarction anxiety. Geranium is also used traditionally for circulation and blood pressure.

• gingerScientific

  Ginger influences multiple cardiovascular risk factors. RCTs and systematic reviews document reductions in LDL, triglycerides, blood pressure, inflammation markers, and insulin resistance. Its anti-atherogenic effects are mediated by antioxidant inhibition of lipid peroxidation, COX/LOX anti-inflammatory activity, and vasodilatory properties.

• ginkgo bilobaScientific

  Ginkgo biloba (as standardized extract EGb 761) has been studied in multiple clinical trials for cardiovascular applications, particularly peripheral arterial disease and intermittent claudication. Proposed mechanisms include vasorelaxation via nitric oxide potentiation, antiplatelet activity, antioxidant effects, and improved microvascular perfusion. However, the large randomized GEM trial (n=3,069) found no reduction in major cardiovascular events or mortality. Clinical evidence is most supportive for peripheral vascular disease outcomes, though even there the Cochrane review found only modest, inconsistent benefit.

• ginsengScientific

  Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that ginseng (Panax ginseng / Panax quinquefolius) produces modest but statistically significant reductions in systolic blood pressure, LDL cholesterol, total cholesterol, and inflammatory markers (CRP, IL-6) in adults. Its active constituents—ginsenosides—promote endothelial nitric oxide (NO) release, endothelium-dependent vasodilation, and reduce platelet aggregation, oxidative stress, and atherosclerotic progression. Evidence quality is promising but heterogeneous, and large confirmatory RCTs are still needed.

• ginsenosidesScientific

  Ginsenosides, the primary bioactive constituents of Panax ginseng, have been extensively studied for cardiovascular benefits including antioxidative, anti-inflammatory, anti-apoptotic, vasodilatory, antithrombotic, and lipid-modulating effects. Human clinical evidence exists—particularly for blood pressure reduction and vascular function—though it remains limited in scale and consistency. The bulk of mechanistic evidence comes from robust preclinical and in vitro work, with clinical translation still in early stages.

• GLA (gamma linolenic acid)Scientific

  GLA has multiple well-documented effects on the cardiovascular system: reducing triglycerides, LDL-cholesterol, platelet aggregation, thromboxane B2, and blood pressure, while increasing HDL-cholesterol, prostacyclin, and bleeding time. These cumulative effects constitute a meaningful cardioprotective profile supported by clinical trial data.

• glucomannanScientific

  Glucomannan beneficially modifies multiple cardiovascular risk biomarkers. Meta-analyses confirm significant reductions in LDL cholesterol, total cholesterol, and triglycerides — all established cardiovascular risk factors. One RCT also found systolic blood pressure reduction in high-risk diabetic patients. EFSA has approved health claims for glucomannan's effect on blood cholesterol maintenance.

• glycineScientific

  Glycine supports cardiovascular health by boosting glutathione to protect endothelial cells from oxidative stress, inhibiting platelet aggregation, attenuating cardiac inflammation, and dampening macrophage-driven atherosclerotic processes. GlyNAC RCTs in older adults showed improved endothelial function and cardiac benefits. Animal studies demonstrate glycine protects cardiomyocytes against ischemia-reperfusion injury.

• glycitinScientific

  Glycitein demonstrates dual cardioprotective mechanisms: lowering blood pressure via eNOS activation and improving lipid profiles via PPAR-γ regulation. Soy isoflavone class evidence documents favorable effects on arterial compliance, LDL cholesterol, and triglycerides in postmenopausal women and diabetic patients. Cardiovascular disease is one of three primary clinical domains of glycitein's established therapeutic activity.

• goji berryScientific

  Goji berry polysaccharides demonstrate multiple cardiovascular-protective effects including lipid modulation (TG, LDL reduction, HDL increase), anti-inflammatory (IL-6, TNF-α reduction), antioxidant, and cardioprotective actions in both animal models and human clinical trials. A cardioprotection RCT (16-week, 15 g/day wolfberry) confirmed improved lipid profiles and oxidative stress in adults.

• goldensealScientific

  Berberine, goldenseal's principal alkaloid, has been studied in clinical trials for cardiovascular benefits including lipid lowering, blood pressure reduction, and preliminary evidence for benefit in congestive heart failure. The NCCIH references a 2022 systematic review and meta-analysis of berberine on cardiovascular risk factors.

• gooseberryScientific

  Amla has the most extensive clinical evidence base of any body system for the cardiovascular system, with multiple RCTs demonstrating improvements in cholesterol, triglycerides, blood pressure, endothelial function, anti-platelet activity, and arterial stiffness. A dedicated systematic review of amla's cardiovascular pharmacology has been published.

• gotu kolaScientific

  Gotu Kola has its most robust clinical evidence in vascular/cardiovascular applications. Multiple RCTs show benefits for chronic venous insufficiency, reduction of ankle edema, improved microcirculation, and potential stabilization of atherosclerotic plaques. The herb acts on connective tissue of vascular walls, reducing capillary permeability and venous hypertension.

• grapeScientific

  Grape seed extract and resveratrol have well-documented effects on the cardiovascular system including blood pressure reduction, endothelial function improvement, anti-platelet activity, LDL oxidation inhibition, and reduced myocardial reperfusion injury. Multiple meta-analyses of RCTs confirm clinically relevant cardiovascular benefits. GSE improves vascular health index scores in clinical trials incorporating multiple circulatory biomarkers.

• grape seedScientific

  Multiple meta-analyses of RCTs demonstrate that GSE significantly reduces systolic blood pressure (by ~6 mmHg) and diastolic blood pressure (by ~2.8 mmHg) across 16 RCTs in 810 subjects. GSE improves endothelial function, reduces aortic stiffness, and lowers LDL and triglycerides. Strongest effects are in younger or obese individuals and those with metabolic disorders.

• grapefruitScientific

  Grapefruit and its flavonoids (naringenin, naringin) have demonstrated clinically meaningful effects on cardiovascular risk factors including LDL cholesterol, triglycerides, blood pressure, and endothelial function in human trials. Naringin inhibits atherosclerotic plaque progression in animal models and reduces biomarkers of endothelial dysfunction. A systematic review of naringin in cardiovascular health (MDPI Nutrients, 2025) identified 62 studies across human and preclinical models.

• greek mountain teaScientific

  Human clinical evidence shows GMT supplementation significantly reduces systolic blood pressure, mean arterial pressure, and resting heart rate, while improving cardiorespiratory capacity (VO2max) and reducing plasma lipid peroxidation. GMT's cerebral blood flow-enhancing effects are additionally relevant to central vascular health.

• green chirettaScientific

  Green chiretta demonstrates cardiovascular-relevant effects including vasorelaxation, hypotension, antithrombotic activity, and cardioprotection against oxidative injury in preclinical studies. A systematic review of 16 in vivo animal studies documents anti-inflammatory and antioxidant cardiovascular effects. Clinical human RCTs targeting cardiovascular endpoints are lacking.

• green teaScientific

  Green tea (Camellia sinensis) has substantial clinical evidence supporting cardiovascular benefits, primarily through its catechin polyphenols—especially EGCG. Multiple RCT-based meta-analyses demonstrate significant reductions in LDL cholesterol, total cholesterol, and blood pressure. Epidemiological data from Asian populations link regular green tea consumption to lower coronary heart disease risk, though results in Western populations are less consistent.

• green-lipped musselScientific

  GLM's lipid extract contains omega-3 PUFAs (EPA, DHA) and free fatty acids that have demonstrated lipid-modifying effects in animal studies. A 2021 PMC study in mice (PMC8367588) found that GLM lipid extracts significantly increased HDL-C and reduced LDL-C, attributed to its high polyunsaturated fatty acid content. A 2021 rat study also demonstrated improved antithrombotic activity following dried mussel consumption. Human-specific cardiovascular RCT evidence for GLM is not yet established.

• guaranaScientific

  Guarana acts on the cardiovascular system through antiplatelet activity (inhibiting thromboxane synthesis), reduction of LDL oxidation, lipid-lowering effects, and anti-inflammatory action in hyperlipidemic states. Epidemiological data link habitual guarana consumption to lower hypertension and cardiovascular metabolic risk. Theobromine in guarana directly influences cardiovascular function via vasodilation.

• guggulScientific

  Guggul exerts multiple actions on the cardiovascular system including lipid modulation, LDL oxidation prevention, anti-platelet aggregation, and promotion of fibrinolysis. Clinical trials document mixed lipid-lowering results but consistent anti-thrombotic effects. Guggulsterones act on hepatic FXR and LDL receptors to modify cholesterol metabolism.

• gymnema sylvestreScientific

  GS exerts multiple beneficial effects on cardiovascular risk factors including reduction of LDL, triglycerides, total cholesterol, and diastolic blood pressure in human studies. Animal models additionally show reduced cardiac apoptosis and arterial pressure. The system-level cardiovascular benefit is supported by a meta-analysis of six clinical studies.

• haliotisScientific

  ACE-inhibitory peptides from multiple Haliotis species and sulphated polysaccharides with anticoagulant properties have been documented in peer-reviewed research. Animal studies confirm antihypertensive effects. These findings position haliotis as having preclinical cardiovascular relevance.

• hawthornScientific

  Hawthorn (Crataegus spp.) has documented human clinical evidence supporting its use for the cardiovascular system, primarily in chronic heart failure (CHF). Multiple randomized controlled trials and a 2008 Cochrane review found significant benefits in exercise tolerance, symptom control, and physiologic outcomes in NYHA class I–III heart failure patients. A 2025 meta-analysis of six RCTs also found statistically significant systolic blood pressure reduction. Evidence is strongest for CHF adjunct therapy; the NCCIH notes results for other cardiac endpoints remain conflicting or insufficient.

• hesperetinScientific

  Hesperetin exerts multiple beneficial effects on the cardiovascular system including lipid modulation, blood pressure reduction, endothelial function improvement, and anti-atherosclerotic activity supported by systematic reviews and RCTs.

• hesperidinScientific

  Hesperidin has extensive documented effects on the cardiovascular system including blood pressure reduction, LDL and total cholesterol lowering, triglyceride reduction, endothelial function improvement, and anti-inflammatory effects on vascular tissue. Multiple RCTs and meta-analyses support these relationships.

• hibiscusScientific

  Hibiscus sabdariffa (roselle) calyx extracts have been evaluated in multiple randomized controlled trials and meta-analyses for antihypertensive effects. A 2022 meta-analysis (Nutrition Reviews, 17 RCTs) found hibiscus reduced systolic blood pressure by approximately 7 mmHg versus placebo. The primary mechanisms involve ACE inhibition and endothelial nitric oxide-mediated vasodilation driven by calyx anthocyanins. Evidence for lipid-lowering effects is less consistent.

• HMR (7-hydroxymatairesinol)Scientific

  HMR inhibits key vascular inflammatory mediators (ICAM-1, VCAM-1, TNF-alpha) in human endothelial cells and monocytes, suppresses LDL oxidation in vitro, and reduced serum lipid parameters in HFD mouse models. Epidemiological data link enterolactone (HMR's major metabolite) with reduced cardiovascular mortality in multiple cohort studies.

• HMR lignanScientific

  HMR demonstrates direct anti-inflammatory activity in human aortic endothelial cells, inhibiting the adhesion molecule expression and monocyte adhesion central to atherosclerosis. Preclinical evidence shows reductions in LDL oxidation, dyslipidemia, and hepatic steatosis. Epidemiological data link enterolactone (HMR's metabolite) with reduced cardiovascular risk, though human interventional trials are lacking.

• hollyScientific

  I. aquifolium saponin and terpenoid fractions have demonstrated effects on cardiovascular-relevant gene expression (LOX-1 downregulation in aorta) and lipid parameters (reduced LDL, cholesterol) in preclinical models. Traditional use includes cardiac stimulant activity attributed to related holly species.

• honeyScientific

  Honey consumption reduces multiple cardiovascular risk factors including total cholesterol, LDL-C, triglycerides, CRP, and fasting blood glucose in controlled human trials. GRADE-assessed meta-analyses confirm modest but statistically significant cardiometabolic benefits. Honey's polyphenols reduce oxidative stress and LDL oxidation, key processes in atherogenesis.

• honeysuckleScientific

  A 2025 PMC systematic review documented honeysuckle's anti-inflammatory role in cardiovascular diseases including coronary atherosclerosis, myocardial ischemia-reperfusion injury, hypertension, arrhythmia, and heart failure via preclinical evidence. Bioactive constituents chlorogenic acid and luteolin modulate key cardiovascular inflammatory pathways. Clinical trial data are lacking.

• horse chestnutScientific

  HCSE has the strongest and most replicated clinical evidence base among herbal supplements for a cardiovascular condition: chronic venous insufficiency. Multiple RCTs and a Cochrane systematic review of 17 trials support its efficacy. Aescin improves venous tone, reduces capillary permeability, decreases blood viscosity, and modulates vascular inflammatory pathways.

• huckleberryScientific

  Vaccinium anthocyanins have demonstrated cardioprotective effects across multiple human RCTs and meta-analyses, including lipid profile improvement, endothelial function enhancement, and reduction in inflammatory CVD biomarkers. Huckleberry shares this phytochemical profile. Traditional uses also consistently linked huckleberry to heart and vascular protection.

• hyacinth beanScientific

  Preclinical pharmacology studies demonstrate cardiovascular-relevant activity including hypolipidemic, antidiabetic, and anti-obesity effects that collectively reduce cardiovascular risk factors in animal models. Potassium content supports cardiovascular function, and traditional use in Namibia documents root use for heart conditions.

• hydroxymatairesinolScientific

  HMR protects vascular endothelial cells by blocking TNF-α-driven NF-κB activation, reducing ICAM-1 and VCAM-1 adhesion molecule expression, and upregulating Nrf2/HO-1 antioxidant defense. These mechanisms are directly relevant to atherogenesis and endothelial dysfunction. HMR's antioxidant and anti-inflammatory properties have been confirmed in human aortic and vascular endothelial cell models. Human cardiovascular trials are lacking.

• indian baelScientific

  Bael extracts exert cardioprotective effects demonstrated in isoproterenol-induced myocardial infarction animal models, normalizing cardiac enzymes, restoring antioxidant status, reducing lipid peroxidation in cardiac tissue, and improving lipid profiles including cholesterol and triglycerides. Traditional Ayurvedic use for heart disorders is well-documented.

• indian gum arabic treeScientific

  Gum arabic from Acacia arabica demonstrably modifies multiple cardiovascular risk factors in human clinical trials. Effects on blood pressure, lipid profiles, visceral adiposity, and inflammatory markers have been confirmed across multiple RCTs. The 2023 systematic review (29 trials) confirms cardiovascular-relevant outcomes.

• indian sarsparillaScientific

  Cardioprotective and anti-thrombotic properties of H. indicus are documented in multiple preclinical studies. A published study assessed cardioprotective effects against doxorubicin-induced oxidative stress in mice. Ayurvedic texts additionally classify the plant as anti-atherogenic.

• indian tinosporaScientific

  T. cordifolia has been noted for cardioprotective activity in preclinical models. A PMC animal study demonstrated antiarrhythmic effects in CaCl2-induced arrhythmia, with T. cordifolia normalizing ECG parameters and modulating plasma electrolytes. A human trial found significant reductions in exercise-induced systolic and diastolic blood pressure. Lipid-lowering clinical data also support cardiovascular relevance.

• inositolScientific

  Inositol modulates cardiovascular risk factors through insulin-sensitizing, lipid-lowering, and blood-pressure-reducing actions. Clinical meta-analyses confirm significant reductions in both systolic and diastolic blood pressure, as well as improvements in lipid profiles, across multiple RCTs. These effects collectively reduce the cardiometabolic risk burden associated with insulin resistance and metabolic syndrome.

• inositol nicotinateScientific

  The cardiovascular system is the primary body system for which IHN has the most clinical evidence. Its established mechanisms include vasodilation (via prostaglandin-mediated niacin activity), lipid lowering (reducing LDL, triglycerides, VLDL; raising HDL), and fibrinolytic enhancement. Clinical trials—particularly for Raynaud's phenomenon and intermittent claudication—directly target peripheral vascular outcomes. Lipid-lowering trials also address systemic cardiovascular risk.

• inula racemosaScientific

  I. racemosa has multiple lines of scientific evidence supporting cardiovascular system effects: cardioprotection against ischemic injury in animals, beta-adrenergic blocking activity, anti-anginal effects in human reports, ECG improvement in IHD patients, and hypolipidemic effects. It is among the most studied aspects of this plant's pharmacology.

• ironScientific

  Iron deficiency is present in approximately 50% of heart failure (HF) patients and is independently associated with worse clinical outcomes, reduced exercise capacity, and increased hospitalization regardless of anemia status. Multiple RCTs of intravenous ferric carboxymaltose (FCM) in HF patients have shown improvements in quality of life and exercise capacity, and current ACC/AHA and ESC guidelines recommend IV iron supplementation in HF with reduced or mildly reduced ejection fraction and confirmed iron deficiency.

• isomalto-oligosaccharideScientific

  IMO's demonstrated reductions in total cholesterol, LDL-associated lipids, triglycerides, and increases in HDL-C in human clinical trials represent direct cardiovascular risk factor modification. A 4-week clinical trial reported decreased cardiac risk ratio scores with IMO-fortified food intake. EFSA reviewed cardiovascular-relevant cholesterol claims for IMO.

• jiaogulanScientific

  Jiaogulan exerts multiple documented effects on the cardiovascular system: lowering blood pressure via nitric oxide, reducing LDL and triglycerides, raising HDL, inhibiting platelet aggregation, and protecting endothelium from oxidative damage. These effects are supported by clinical RCTs and mechanistic studies.

• jujubeScientific

  Jujube has been evaluated for cardiovascular risk factor modification in human RCTs, with demonstrated effects on blood glucose, triglycerides, LDL-C, and total cholesterol in T2D patients. Polyphenols support endothelial function and LDL oxidation protection. A meta-analysis pooled 4 RCTs confirming lipid/glycemic benefits. No direct cardiac or arterial outcome RCTs have been published.

• kaleScientific

  Kale improves multiple cardiovascular risk factors including LDL, HDL, blood pressure, and triglycerides in clinical studies. Its flavonoids, fiber, potassium, and vitamin K1 support arterial health, lipid profiles, and endothelial function. A 12-week clinical trial in hypercholesterolemic men demonstrated significant coronary artery disease risk factor improvement.

• kelpScientific

  Kelp and its compounds (fucoidan, alginate, bioactive peptides, inorganic nitrate) have demonstrated blood pressure reduction, LDL and triglyceride lowering, antithrombotic, and anti-atherosclerotic effects in human studies. A 2025 meta-analysis of 29 RCTs confirmed significant blood pressure reduction from edible algae. Fucoidan modulates platelet aggregation and extends clotting time in human clinical studies.

• kidney beansScientific

  Kidney beans exert multiple evidence-based cardiovascular benefits: reducing LDL cholesterol through soluble fiber and butyrate pathways, lowering blood pressure via ACE inhibition and potassium/magnesium content, improving arterial stiffness (pulse wave velocity), and protecting blood vessels via antioxidant polyphenols and tocopherols.

• knotweedScientific

  Knotweed's resveratrol and polydatin act on multiple cardiovascular targets: improving endothelial function, reducing blood pressure, inhibiting LDL oxidation, lowering triglycerides, and inhibiting platelet aggregation. Human RCTs and meta-analyses support beneficial effects on blood pressure, flow-mediated dilation, and insulin resistance. TCM uses Hu Zhang for blood-stasis cardiovascular conditions.

• krill oilScientific

  Multiple randomized controlled trials and meta-analyses provide clinical evidence that krill oil supplementation meaningfully reduces cardiovascular risk factors, particularly triglycerides and LDL cholesterol, while raising HDL cholesterol. Its omega-3 fatty acids (EPA and DHA), delivered in phospholipid form alongside the antioxidant astaxanthin, underpin its cardioprotective mechanisms. Evidence is promising but overall RCT sample sizes remain modest, and direct reductions in cardiovascular events have not yet been demonstrated.

• kudzuScientific

  Puerarin from kudzu root has extensive documented effects across the cardiovascular system, including vasodilation, anti-atherosclerotic activity, cardioprotection in ischemia, antihypertensive effects, and lipid modulation. Clinical use in China for coronary heart disease, angina, myocardial infarction, and stroke is well established. Preclinical studies comprehensively map the mechanistic pathways.

• L-arginineScientific

  L-arginine is the sole substrate for nitric oxide (NO) synthesis via nitric oxide synthase, making it a key regulator of vascular tone and endothelial function. Clinical trials and meta-analyses confirm it reduces systolic and diastolic blood pressure in hypertensive populations and improves endothelial function in patients with cardiovascular risk factors. However, effects are most pronounced when endothelial dysfunction is present (e.g., elevated ADMA), and evidence is mixed or absent in healthy individuals without vascular impairment. One large post-MI trial reported higher mortality in the L-arginine group, underscoring that benefit is context-dependent.

• l-carnitineScientific

  L-carnitine is integrally involved in cardiac energy metabolism and has been studied in ischemic heart disease, heart failure, arrhythmia, and peripheral vascular disease. Meta-analyses show reductions in mortality, arrhythmias, and angina post-MI. The heart is the organ with the highest dependence on fatty acid oxidation, making carnitine central to cardiac bioenergetics.

• L-carnosineScientific

  L-carnosine scavenges acrolein and reactive aldehydes that damage vascular endothelium, and its urinary conjugates are associated with cardiovascular disease risk markers. Human RCTs show modest effects on cardiometabolic risk factors (glucose, triglycerides, insulin) in metabolic disease populations. A 14-week RCT in pre-diabetes/T2D found no significant effect on endothelial function or arterial stiffness.

• L-citrullineScientific

  L-Citrulline is an endogenous amino acid that serves as a precursor to L-arginine, the substrate for endothelial nitric oxide synthase (eNOS), thereby increasing nitric oxide (NO) bioavailability and promoting vasodilation. Multiple randomized controlled trials and meta-analyses demonstrate clinically meaningful reductions in both systolic and diastolic blood pressure, improvements in flow-mediated dilation (a marker of endothelial function), and benefits in populations with heart failure with preserved ejection fraction (HFpEF). Evidence is strongest for blood pressure reduction and endothelial function; effects on arterial stiffness are more variable across studies.

• L-cysteineScientific

  L-cysteine/NAC supports cardiovascular health by replenishing glutathione to reduce vascular oxidative stress and endothelial dysfunction, inhibiting LDL oxidation and atherosclerosis progression, and exhibiting vasodilatory properties. The transsulfuration pathway positions cysteine as a key downstream metabolite of the cardiovascular risk factor homocysteine.

• L-glutathioneScientific

  The cardiovascular system is directly impacted by oxidative stress-driven GSH depletion; low GSH is associated with endothelial dysfunction, atherosclerosis, and increased cardiovascular risk. Human trials with sublingual L-GSH have demonstrated reduced LDL cholesterol and improved arterial stiffness in at-risk individuals. GSH is a key regulator of NO bioavailability essential for vascular tone.

• L-glycineScientific

  Glycine is a structural component of glutathione, which is essential for vascular and cardiac function. Clinical GlyNAC trials document improved endothelial function. Preclinical studies show glycine protects the heart against cardiotoxin-induced injury by reducing oxidative stress, inflammation, and fibrosis. Glycine also reduces platelet aggregation and improves microvascular perfusion.

• L-histidineScientific

  L-histidine is the primary buffer in HTK cardioplegic solution used in cardiac surgery globally, protecting the myocardium from ischemia-reperfusion injury. In CKD cohorts, low plasma histidine independently predicts cardiovascular disease, carotid plaques, and mortality. Carnosine, a histidine dipeptide, reduces cardiovascular risk factors (CRP, HbA1c, waist circumference) in meta-analyses of RCTs.

• L-prolineScientific

  The cardiovascular system's structural integrity—arterial walls, cardiac muscle, and valves—depends on collagen types I and III, both of which require L-proline for synthesis. The proline dehydrogenase (PRODH) enzyme connects proline catabolism to mitochondrial electron transport, ROS signaling, and cardiac bioenergetics. Collagen peptide RCTs have shown proline-rich supplementation reduces systolic and diastolic blood pressure in postmenopausal women.

• L-theanineScientific

  L-theanine has been studied for multiple cardiovascular effects including blood pressure attenuation, cardioprotection against ischemia-reperfusion injury, lipid profile improvement, and anti-atherosclerotic activity. Human clinical evidence exists primarily for stress-induced blood pressure reduction and heart rate modulation. A 2026 review in ScienceDirect provides the first comprehensive synthesis of L-theanine's effects across cardiovascular disease contexts. Preclinical data demonstrates significant cardioprotective mechanisms involving antioxidant and anti-inflammatory pathways.

• LA (linoleic acid)Scientific

  LA is a major dietary PUFA with well-documented cardiovascular effects: it lowers LDL cholesterol, is inversely associated with coronary heart disease risk in large prospective cohorts, reduces chronic inflammatory biomarkers (CRP, IL-6), and is associated with lower stroke risk. A meta-analysis of 40 RCTs and multiple large prospective cohort analyses support these effects.

• lactobacillus caseiScientific

  L. casei Shirota has been studied for improving intestinal permeability in metabolic syndrome, reducing LPS translocation that drives cardiovascular inflammatory risk. Combination probiotic formulations containing L. casei have contributed to improved lipid profiles in clinical trials. L. casei's BSH (bile salt hydrolase) activity documented in vitro provides a mechanistic basis for cholesterol modulation relevant to cardiovascular health.

• lactobacillus plantarumScientific

  L. plantarum supports cardiovascular health through clinically documented reductions in LDL-C, total cholesterol, triglycerides, and blood pressure, particularly in at-risk individuals. An RCT in stable coronary artery disease also demonstrated suppression of systemic inflammation.

• lavenderScientific

  Lavender has demonstrated cardioprotective effects in preclinical models, attributed to its antioxidant properties. Multiple clinical RCTs have measured reductions in blood pressure and heart rate as physiological outcomes of lavender aromatherapy. Oral Silexan has been linked to reduced somatic anxiety symptoms including palpitations in clinical trials.

• lecithinScientific

  Lecithin influences the cardiovascular system through its active role as a substrate for LCAT, which mediates reverse cholesterol transport and HDL metabolism. Human studies show improvements in lipid profiles in hypercholesterolemic individuals, and a 2024 comprehensive review (PMC) examined lecithin's role in atherosclerosis prevention and cardiovascular risk reduction.

• lemonScientific

  Lemon's flavonoids, vitamin C, and potassium collectively support cardiovascular health through clinically demonstrated reductions in blood pressure, LDL cholesterol, triglycerides, and LDL oxidation. Multiple RCTs and meta-analyses document protective effects of citrus bioactives on cardiovascular risk factors.

• lemon balmScientific

  Lemon balm exerts multiple clinically demonstrated cardiometabolic effects: reducing systolic blood pressure (meta-analysis of 7 RCTs), reducing palpitations (RCT), lowering total cholesterol and LDL (meta-analyses), and potentially lowering triglycerides. ACE inhibition by rosmarinic acid, antioxidant activity, and antispasmodic effects on vascular smooth muscle are the principal mechanisms.

• lemongrassScientific

  Lemongrass has documented effects on multiple cardiovascular parameters: blood pressure reduction in human studies, vasorelaxation via endothelial mechanisms, weak diuretic activity, and antioxidant protection of vascular endothelial cells. The 2022 comprehensive review confirmed human clinical evidence for antihypertensive effects of lemongrass tea.

• lentinula edodes myceliaScientific

  LEM supports cardiovascular health through anti-atherogenic, lipid-lowering, and homocysteine-reducing mechanisms demonstrated in multiple preclinical models. LEM reduced atherosclerotic lesion indices in rabbits and lowered LDL, cholesterol, and triglycerides in rodent models.

• lignansScientific

  Lignans exert multiple cardioprotective effects including reductions in total and LDL cholesterol, blood pressure, C-reactive protein, and coronary heart disease risk in large prospective cohort studies. Both flaxseed lignan and sesamin supplement trials provide human-level evidence. The mechanisms involve antioxidant, anti-inflammatory, and mild estrogenic actions of enterolignans.

• lilacScientific

  Syringin from S. vulgaris has documented hypotensive activity, and polyphenols from the plant's flowers and leaves significantly mitigated blood flow reduction in a mouse blood stasis model. A 2026 PMC study examined S. vulgaris flower extract for modulation of the coagulation process in human plasma. Cardioprotective activity is confirmed in preclinical studies for the genus.

• limeScientific

  Lime supports cardiovascular health through multiple mechanisms: inhibition of LDL oxidation (in vitro human LDL study), reduction of total cholesterol, LDL, and triglycerides in citrus class RCTs, modest diastolic blood pressure reduction in a meta-analysis, and epidemiological associations between citrus flavanone intake and reduced cardiovascular mortality.

• lotus seedScientific

  Lotus seed alkaloids support cardiovascular health through antihypertensive (eNOS/NO, ACE-inhibitory), anti-arrhythmic, antioxidant, and anti-inflammatory mechanisms robustly demonstrated in animal models. TCM classically assigns lotus seed to the Heart meridian for cardiovascular support.

• luteinScientific

  Higher dietary intake and blood concentrations of lutein are consistently associated with reduced risk of coronary heart disease and stroke in meta-analyses of epidemiological studies. Lutein's anti-inflammatory and antioxidant actions appear to attenuate atherosclerosis progression. A 2016 systematic review and meta-analysis found a 12% lower CHD risk and 18% lower stroke risk associated with the highest versus lowest tertile of lutein exposure.

• luteolinScientific

  Luteolin exerts broad cardioprotective effects across the cardiovascular system including anti-atherosclerotic, anti-hypertrophic, antihypertensive, lipid-lowering, and endothelial-protective actions, documented in both animal models and a human nutraceutical RCT.

• lycheeScientific

  Lychee polyphenols exert multiple effects on the cardiovascular system: ACE inhibition (blood pressure regulation), antioxidant protection of vascular endothelium, anti-inflammatory suppression of atherosclerosis-driving cytokines, triglyceride reduction in human trials, and microcirculation enhancement documented clinically. Animal studies show LDL reduction and HDL elevation. Oligonol's manufacturer-supported human trial data further documents cardiovascular-relevant outcomes.

• lycopeneScientific

  Multiple clinical trials, systematic reviews, and meta-analyses support lycopene's cardiovascular benefits, primarily through antioxidant, anti-inflammatory, and antihypertensive mechanisms. Evidence is strongest for reductions in systolic blood pressure and LDL oxidation, with more mixed results for lipid profiles. A 2026 umbrella review of meta-analyses confirmed high-certainty evidence for blood pressure lowering effects from daily lycopene intake of 5–30 mg.

• macadamiaScientific

  The cardiovascular system is the best-evidenced target of macadamia nut consumption. Clinical trials demonstrate reductions in total cholesterol and LDL-C, improved atherogenic lipid ratios, and attenuation of oxidative stress and inflammation relevant to arterial health. These effects are primarily attributable to the high MUFA content, flavonoids, and tocotrienols.

• magnesiumScientific

  Magnesium plays a well-documented role in cardiovascular health, supported by epidemiological studies, RCTs, and meta-analyses. It regulates cardiac excitation, vascular tone, and endothelial function, with lower magnesium levels consistently associated with higher risks of arrhythmia, hypertension, coronary artery disease, and heart failure. Supplementation shows clinically meaningful blood pressure reductions primarily in hypertensive or magnesium-deficient individuals. Evidence for acute myocardial infarction outcomes remains conflicting across large trials.

• magnoliaScientific

  Honokiol and magnolol demonstrate cardioprotective effects in preclinical models, including reductions in total cholesterol, LDL, and triglycerides, alongside blood pressure reduction. A PMC review (PMC12072210) specifically examined cardioprotective activity of M. officinalis constituents. All direct cardioprotective evidence is currently limited to animal and in vitro models.

• maitake mushroomScientific

  Maitake's beta-glucans, polysaccharides, and antioxidant compounds act on multiple cardiovascular risk factors including blood pressure, cholesterol, triglycerides, and vascular nitric oxide signaling. Preclinical data is robust; limited but suggestive human data exists. Traditional use in Asia included maitake for hypertension.

• mangoScientific

  Human RCTs demonstrate mango consumption produces clinically relevant improvements in multiple cardiovascular risk factors: reductions in systolic blood pressure, LDL cholesterol, total cholesterol, and improved endothelial function (flow-mediated vasodilation). These effects are observed across multiple independent clinical trials.

• mangosteenScientific

  Mangosteen xanthones display cardioprotective, antiatherosclerotic, antiplatelet, and vasorelaxant properties in laboratory and animal studies. A human prospective study in high cardiovascular-risk patients showed reduced lipid peroxidation markers after 90 days of supplementation. Clinical combination-product trials also showed reductions in serum cholesterol and triglycerides in obese subjects.

• maqui berryScientific

  Maqui berry exerts multiple beneficial effects on the cardiovascular system: reducing plasma oxidized LDL in a double-blind RCT, improving LDL/HDL profiles in a 3-month clinical trial, and showing epidemiological associations with reduced heart attack and hypertension risk via dietary anthocyanin intake. Preclinical data support improved endothelial function and reduced vascular oxidative stress.

• marjoramScientific

  Preclinical studies demonstrate cardioprotective, antihypertensive, lipid-lowering, and anti-platelet effects of marjoram. Traditional use in Moroccan and Iranian medicine specifically includes cardiovascular benefits.

• mastic gumScientific

  Mastic gum modulates multiple cardiovascular risk factors in human trials: modest total cholesterol reduction, protection of LDL from oxidation, and favorable effects on aortic blood pressure and augmentation index in hypertensive patients. A 2024 PMC narrative review concluded accumulating evidence supports CMG as a cardiometabolic phytotherapeutic. No hard cardiovascular endpoint trials (mortality, MACE) have been conducted.

• melatoninScientific

  Melatonin acts directly on the cardiovascular system via MT1/MT2 receptors in cardiac tissue and blood vessels, regulating heart rate, blood pressure, and protecting against ischemia-reperfusion injury. Epidemiological data consistently show inverse relationships between endogenous melatonin and cardiovascular disease burden. Clinical trials support nocturnal blood pressure reduction.

• methylcobalaminScientific

  MeCbl modulates cardiovascular health primarily through homocysteine lowering. Elevated homocysteine is directly toxic to endothelial cells and promotes atherosclerosis; MeCbl's role as cofactor for methionine synthase positions it as a key regulator of vascular homocysteine levels. Clinical evidence from RCTs and observational data supports this mechanism.

• milk thistleScientific

  Milk thistle reduces LDL cholesterol and total cholesterol, which are primary cardiovascular risk factors. Meta-analyses in type 2 diabetic populations confirm lipid profile improvements. Research published in the Journal of Agricultural and Food Chemistry (2020) showed potential cardiovascular system benefits. LDL reduction is the primary cardiovascular mechanism documented.

• millet seedScientific

  Millet seed supports cardiovascular health by reducing total cholesterol, LDL-C, VLDL-C, triglycerides, and blood pressure while raising HDL-C. Meta-analyses of approximately 19 human studies confirm these effects, moving lipid values from above-normal to normal ranges. Bioactive peptides with ACE-inhibitory activity provide an additional antihypertensive mechanism.

• momordicaScientific

  Momordica charantia has been studied for multiple cardiovascular risk factor modifications including glycaemia, dyslipidaemia, blood pressure, and oxidative stress. Human RCT meta-analyses show consistent glycaemic improvements but non-significant effects on lipids and blood pressure. Momordicine I has specific preclinical cardioprotective activity.

• morindaScientific

  Morinda citrifolia exerts multiple cardiovascular effects: antihypertensive activity via GLP-1R-AMPK-eNOS endothelial signalling, antidyslipidaemic effects on cholesterol and triglycerides with clinical trial support, anti-AGE endothelial protection, and anti-inflammatory reduction of hs-CRP. These collectively support cardiovascular system health.

• morusScientific

  Morus exerts multiple clinically documented cardioprotective effects: reducing blood pressure, LDL-cholesterol, triglycerides, CRP, and improving endothelial function. A 2025 meta-analysis of 15 RCTs confirmed pooled cardiovascular risk factor improvements. Mechanisms include ACE inhibition, NO upregulation, and anti-inflammatory activity.

• motherwortScientific

  Motherwort exerts documented effects across the cardiovascular system including hypotension, negative chronotropy, vasorelaxation, antiarrhythmic effects, improved coronary blood flow, and antiatherosclerotic activity. These are supported by human pilot data, multiple meta-analyses of RCTs (for hemostasis), and extensive preclinical pharmacology. Germany's Commission E and the EMA have formally recognized cardiovascular indications.

• mugwortScientific

  A. vulgaris has documented hypotensive and vasodilatory effects demonstrated in animal models and supported by moxibustion RCTs. Hypolipidemic effects normalizing cholesterol and triglyceride profiles are shown in rodent studies. Antithrombotic activity of essential oil constituents is documented in vitro. Collectively, multiple cardiovascular-relevant mechanisms are pharmacologically established.

• mulberryScientific

  Clinical trial evidence shows mulberry supplementation lowers blood pressure, LDL cholesterol, triglycerides, and CRP—all major cardiovascular risk factors. A 2025 meta-analysis of 15 RCTs confirmed these effects. Preclinical evidence also shows anti-atherosclerotic and endothelial-protective properties.

• mustardScientific

  Mustard seed omega-3 fatty acids, plant sterols, isothiocyanates, and minerals (magnesium, potassium, selenium) collectively support cardiovascular function through complementary mechanisms including lipid regulation, blood pressure modulation, anti-inflammatory activity, and antioxidant protection of vascular endothelium.

• myrobalanScientific

  TC protects the cardiovascular system via antioxidant, anti-inflammatory, and lipid-lowering mechanisms, with a clinical RCT demonstrating improved endothelial function in diabetic patients and preclinical evidence of VSMC proliferation inhibition relevant to atherosclerosis prevention.

• NAC (N-acetyl cysteine)Scientific

  NAC has multiple verified effects on the cardiovascular system including homocysteine reduction, blood pressure lowering, anti-platelet effects, reduction of oxidized LDL, and perioperative cardiac protection. These have been demonstrated in human RCTs and meta-analyses across diverse cardiovascular populations.

• naringinScientific

  Naringin exerts multi-target cardiovascular protection including endothelial function improvement, myocardial protection, blood pressure reduction, lipid lowering, and anti-atherosclerotic activity. A 2025 PRISMA systematic review of 62 studies confirmed consistent cardioprotective effects. Limited human trial evidence supports improved lipid profiles and arterial stiffness.

• nattokinaseScientific

  Nattokinase, a serine protease derived from the fermented soybean food natto, has multiple mechanisms relevant to cardiovascular health, including fibrinolysis, blood pressure reduction, and anti-atherosclerotic activity. Multiple randomized controlled trials and a 2023 systematic review and meta-analysis (6 RCTs, 546 participants) confirm a statistically significant antihypertensive effect. Evidence on lipid-lowering is mixed and appears dose-dependent, while a 3-year RCT found no significant effect on subclinical atherosclerosis progression at a low dose. Overall, the cardiovascular relationship is supported by meaningful, albeit still-growing, human clinical evidence.

• nattozimesScientific

  Nattokinase exerts multiple evidence-based effects on the cardiovascular system, including fibrinolytic, antihypertensive, antiplatelet, anti-atherosclerotic, and hemorheological actions. These have been confirmed in multiple human RCTs and summarized in peer-reviewed systematic reviews.

• nettleScientific

  Nettle has demonstrated effects on multiple cardiovascular risk factors in human and animal studies, including reductions in blood pressure, total cholesterol, LDL, and triglycerides, and increases in HDL. A review of clinical and preclinical studies confirmed consistent antihypertensive and lipid-lowering activity. Mechanisms include antioxidant inhibition of lipid peroxidation, HMG-CoA reductase inhibition, and nitric oxide–mediated vasodilation.

• nicotinamide ribosideScientific

  Multiple human RCTs document NR's effects on the cardiovascular system, including reductions in systolic blood pressure, arterial stiffness (pulse wave velocity), and improved endothelial function. In heart failure patients, NR raises myocardial NAD+ and correlates with reduced systemic inflammation. The NICE RCT tested NR in 90 PAD patients for walking capacity and skeletal muscle health.

• NMN (β-nicotinamide mononucleotide)Scientific

  NMN has been studied across multiple components of cardiovascular health including arterial stiffness, blood pressure, myocardial ischemia-reperfusion injury, heart failure, endothelial function, and triglycerides. Both in vivo and in vitro evidence demonstrates cardiovascular protective actions; several human clinical studies confirm safety and some cardiometabolic benefits.

• nopalScientific

  Human RCTs and meta-analyses show nopal supplementation improves multiple cardiovascular risk factors: reduces total cholesterol, LDL, and triglycerides; increases HDL; and lowers systolic and diastolic blood pressure. These effects are documented across dyslipidemic, obese, and metabolic syndrome populations. Anti-inflammatory and antioxidant properties provide additional cardiovascular protection. Polyphenols and soluble fiber are the principal bioactive mediators.

• nut grassScientific

  C. rotundus demonstrates cardioprotective, antihypertensive, anti-platelet, and antilipidemic activities in preclinical models, with lipid-lowering effects confirmed in human RCTs. Ethnobotanical use for atherosclerosis is also recorded. These collectively implicate the cardiovascular system as a primary target.

• oatScientific

  Oat β-glucan and avenanthramides exert multiple cardiovascular benefits: LDL cholesterol reduction, blood pressure modulation in hypertensive individuals, arterial anti-inflammatory effects, and reduced Framingham CVD risk scores in RCTs. The FDA issued a health claim for oat soluble fiber and coronary heart disease in 1996.

• okraScientific

  Okra beneficially modulates core cardiovascular risk factors including TC, LDL-C, FBG, and HbA1c in clinical trials. Preclinical evidence demonstrates vasoprotective anti-inflammatory activity via LOX-1/NF-κB inhibition and cytokine suppression. CRP reduction has been shown in a 2023 double-blind clinical trial.

• oleanolic acidScientific

  OA has documented anti-atherosclerotic, antihypertensive, cardioprotective, and hypolipidemic effects relevant to the entire cardiovascular system. It protects the heart from ischemia-reperfusion injury, lowers lipid levels, prevents atherosclerotic plaque formation, and exerts antihypertensive effects through multiple mechanisms.

• oleic acidScientific

  Oleic acid is the most studied dietary fat in relation to cardiovascular system health, with an FDA qualified health claim for coronary heart disease risk reduction. It lowers LDL cholesterol, raises HDL, reduces LDL oxidisability, and supports endothelial function. Multiple RCTs and systematic reviews confirm its cardiometabolic benefits when substituted for saturated fats.

• oliveScientific

  Olive and olive leaf extract provide multi-faceted cardiovascular system benefits documented in human RCTs: blood pressure reduction, LDL and total cholesterol lowering, triglyceride reduction, oxidized LDL protection, antiplatelet activity, and endothelial function improvement. The EFSA has formally approved a health claim for olive polyphenols protecting blood lipids from oxidative damage.

• olive oilScientific

  Olive oil, particularly extra-virgin olive oil (EVOO), has robust clinical and epidemiological evidence supporting its cardiovascular benefits. Multiple meta-analyses and large randomized controlled trials show it reduces the risk of cardiovascular events, CVD mortality, and coronary heart disease. Its primary mechanisms involve polyphenol-driven improvements in endothelial function, lipid oxidation, inflammation, and blood pressure. Evidence is strongest in high-risk populations.

• omega-3 fatty acidsScientific

  Omega-3 fatty acids (EPA and DHA) have extensive clinical evidence supporting their role in cardiovascular health, most robustly in lowering triglycerides and, at high pharmaceutical doses of purified EPA, reducing major cardiovascular events. Evidence from large RCTs and meta-analyses is substantial but nuanced: benefits are strongest for triglyceride reduction and cardiovascular mortality, while effects on other endpoints (MI, stroke, all-cause mortality) are inconsistent across trials. High-dose purified EPA (icosapent ethyl) has the strongest outcomes evidence, whereas lower-dose mixed EPA+DHA supplements show more limited clinical benefit.

• omega-6 fatty acidsScientific

  Omega-6 fatty acids, primarily linoleic acid, have well-documented cardiovascular effects. High-quality Cochrane evidence shows modest but significant reduction in total cholesterol. Longitudinal cohort studies consistently associate higher LA biomarker status with lower coronary heart disease risk. Controlled feeding trials show that replacing saturated fat with LA reduces LDL cholesterol, triglycerides, and apolipoprotein B, improving overall lipoprotein profiles.

• omega-7 fatty acidsScientific

  Omega-7 fatty acids influence multiple cardiovascular risk factors. Human RCT data show reductions in hs-CRP, triglycerides, and LDL alongside HDL increases with purified palmitoleic acid. Epidemiological cohorts associate higher plasma palmitoleate with lower metabolic and cardiovascular risk. An NIH-registered Phase 2 trial is ongoing for cardiovascular/lipoprotein endpoints.

• omega-9 fatty acidsScientific

  Omega-9 oleic acid exerts comprehensive cardiovascular benefits: reducing LDL oxidation, improving endothelial function, modestly lowering blood pressure, improving lipid profiles, and reducing major cardiovascular events in large RCTs. OA is the principal active lipid in the Mediterranean dietary pattern, which is guideline-endorsed for cardiovascular prevention.

• onionScientific

  Onion exerts comprehensive cardioprotective effects on the cardiovascular system through antihypertensive, lipid-modifying, anti-thrombotic, and anti-inflammatory mechanisms. Multiple meta-analyses of RCTs confirm significant improvements in blood pressure, LDL, HDL, total cholesterol, and platelet aggregation with onion supplementation.

• ophiopogonScientific

  Ophiopogon japonicus has well-documented cardioprotective, antiarrhythmic, antithrombotic, and anti-atherosclerotic effects supported by preclinical research and clinical formula studies. It is a core ingredient of approved Chinese patent medicines for cardiovascular disease.

• ophiopogon rootScientific

  Ophiopogon root has extensive preclinical and clinical evidence supporting cardiovascular system protection. Its polysaccharides, steroidal saponins, and homoisoflavonoids address myocardial ischemia, arrhythmia, heart failure, thrombosis, and atherosclerosis. Clinical use is established through RCTs of Shenmai and Shengmai injections in China for coronary heart disease and heart failure.

• orangeScientific

  Orange flavonoids, particularly hesperidin, have extensive clinical evidence supporting cardiovascular protection including improvements in LDL cholesterol, total cholesterol, blood pressure in hypertensive individuals, endothelial function, and reduction of inflammatory adhesion molecules. Multiple RCTs and meta-analyses document these effects.

• oreganoScientific

  Oregano's primary constituent carvacrol modulates multiple cardiovascular parameters in preclinical studies, including reducing blood pressure, heart rate, LDL cholesterol, and triglycerides, while inhibiting LDL oxidation. A small human study found oregano extract improved lipid profiles in people with mildly elevated cholesterol. Anti-inflammatory and antioxidant mechanisms are relevant to cardiovascular risk reduction.

• oriental arborvitaeScientific

  P. orientalis leaf extracts have been studied for cardioprotective effects in diabetic cardiomyopathy models, demonstrating reduction of myocardial fibrosis and oxidative stress via Nrf2/HO-1 pathway activation. Antihyperlipidemic activity has also been documented in animal models. Traditional use includes support for blood circulation.

• oryzaScientific

  Oryza sativa bran and its bioactives (gamma-oryzanol, tocotrienols, policosanol, anthocyanins) exert multiple cardiovascular benefits including lipid lowering, antioxidant protection, antiplatelet activity, and anti-inflammatory effects on vascular and cardiac tissue, supported by human and animal studies.

• oyster mushroomScientific

  Multiple human trials show oyster mushroom intake beneficially modifies cardiovascular risk factors: LDL cholesterol, total cholesterol, triglycerides, and blood pressure are consistently reduced. The 2020 systematic review of 8 human trials documented these cardiometabolic benefits. Mechanistically, β-glucan, lovastatin content, ACE-inhibitory peptides, and antioxidant ergothioneine all contribute.

• palm oilScientific

  Palm oil exerts complex effects on the cardiovascular system. Its saturated fat content raises LDL cholesterol, while its tocotrienol fraction inhibits HMG-CoA reductase, reduces arterial inflammation, and has been shown to attenuate brain white matter lesion progression—a surrogate marker of cerebrovascular disease—in a 2-year human RCT. Overall cardiovascular risk from dietary palm oil remains debated.

• palmitic acidScientific

  Clinical cohort, epidemiological, and mechanistic evidence firmly links elevated palmitic acid with adverse cardiovascular outcomes including endothelial dysfunction, atherosclerosis, elevated LDL-cholesterol, and increased MACE risk. The association is one of harm: higher circulating or dietary palmitic acid worsens cardiovascular system function. The mechanism involves endothelial palmitoylation, TLR4-driven vascular inflammation, and proatherogenic lipoprotein changes.

• palmitoleic acidScientific

  POA functions as a lipokine that modulates cardiovascular risk factors including triglycerides, LDL-C, HDL-C, and CRP. Prospective cohort evidence and small RCTs support cardiometabolic benefits, though directionality depends on whether POA is endogenous (de novo lipogenesis marker) or exogenous (dietary/supplemental).

• pantethineScientific

  Pantethine is among the most clinically studied nutritional supplements for cardiovascular risk modification, with more than 28 controlled trials documenting lipid improvements. Its mechanisms include inhibition of cholesterol synthesis enzymes, enhancement of fatty acid oxidation, and antiplatelet activity. Reductions in LDL-C, triglycerides, and non-HDL-C are consistently observed at 600–900 mg/day.

• papayaScientific

  Papaya's constituent nutrients and phytochemicals — lycopene, fiber, potassium, folate, and flavonoids — affect multiple cardiovascular risk factors including LDL cholesterol, blood pressure, homocysteine, and oxidative stress. Animal studies consistently show papaya extracts lower cholesterol, triglycerides, and atherogenic index. The American Heart Association notes lycopene and fiber from papaya as having cardiovascular relevance.

• parsleyScientific

  Parsley exerts multiple beneficial effects on the cardiovascular system, including antihypertensive, antithrombotic, hypolipidaemic, and anti-atherogenic activity, predominantly via its flavone apigenin and folate content. These are supported by consistent preclinical evidence reviewed in a 2024 MDPI Medicines article.

• passionflowerScientific

  Passionflower influences cardiovascular parameters primarily through its anxiolytic and sympatholytic effects. Human trials show stress-induced heart rate and systolic blood pressure elevations are reduced by passionflower extract. Animal models demonstrate direct hypotensive effects of Passiflora edulis peel extract in spontaneously hypertensive rats. Traditional Eclectic herbalism documented passionflower's ability to lower pulse and decrease blood pressure during acute anxiety states.

• peaScientific

  Pea contributes to cardiovascular health via ACE/renin-inhibitory peptides that lower blood pressure, lipid-modulating effects (lower LDL, triglycerides, VLDL; higher HDL), and antioxidant peptides that reduce oxidative stress and inflammation. Both protein and fiber fractions contribute.

• peachScientific

  Peach extracts demonstrate cardiovascular-relevant preclinical activity including inhibition of angiotensin II signaling in vascular smooth muscle cells, reduction of serum triglycerides and cholesterol, and anti-inflammatory effects. The peach kernel has millennia of TCM use for blood stasis in the heart and vessels.

• peanutScientific

  Peanuts beneficially modulate multiple cardiovascular risk factors including LDL cholesterol, TC/HDL ratio, triglycerides, and endothelial function. Phytosterols, MUFA, resveratrol, and fibre are the key active constituents. A systematic review confirmed significant favourable effects on LDL-C, TC, TG, TC:HDL, LDL:HDL, and apoB.

• pearScientific

  Pear polyphenols (catechins, chlorogenic acid, quercetin) modulate vascular endothelial function through nitric oxide release, reduce LDL oxidation, and exert anti-inflammatory effects on vascular tissue. A meta-analysis links apple/pear intake to reduced cardiovascular death and cerebrovascular disease risk in cohort studies. Fiber from pears also lowers LDL cholesterol via bile acid sequestration.

• pectinScientific

  Pectin benefits the cardiovascular system by lowering LDL cholesterol and triglycerides, improving fibrin network structure, modestly reducing blood pressure, and supporting favorable microbiota-heart axis signaling via SCFAs. Multiple human RCTs document cardiovascular risk factor improvements.

• peonyScientific

  Paeoniflorin has been reviewed for cardiovascular protective effects including anti-atherosclerotic, anti-inflammatory, antioxidant, and anti-remodeling properties. A 2023 Frontiers in Pharmacology review confirmed multiple cardiovascular mechanisms, though clinical trials are still required for definitive drug-level recommendations.

• peptidaseScientific

  Certain peptidase/protease enzymes exhibit fibrinolytic activity—degrading fibrin in blood clots—and have been studied as antithrombotic agents. Fibrinolytic serine proteases such as nattokinase and serrapeptase demonstrate measurable thrombolytic activity in vitro and in animal models. Clinical human evidence for oral fibrinolytic peptidases (distinct from intravenous thrombolytics) is limited but growing.

• perillaScientific

  Human RCT data show Perilla leaf powder reduces oxidized LDL, blood pressure, and improves antioxidant markers over 6 months. Seed oil ALA content provides cardiovascular protective effects via lipid-lowering and anti-inflammatory mechanisms. Perilla polyphenols protect vascular endothelial cells from inflammatory damage in human cell models.

• phosphatidylcholineScientific

  PC is a structural component of vascular cell membranes and a substrate for LCAT-mediated HDL cholesterol esterification, central to reverse cholesterol transport. Gut microbial metabolism of PC to TMAO has been linked to CVD risk in large clinical cohorts. PC also modulates homocysteine levels via the betaine pathway.

• phosphorusScientific

  Elevated serum phosphorus is clinically associated with increased cardiovascular disease risk, left ventricular hypertrophy, vascular calcification, and mortality—particularly in chronic kidney disease. Associations also exist in general populations. High phosphorus levels have been linked to irregular heartbeat and coronary artery disease.

• phytosterolsScientific

  Phytosterols are plant-derived sterols with robust clinical evidence for lowering LDL-cholesterol, a primary cardiovascular risk factor. Multiple clinical trials and meta-analyses consistently show that 2 g/day reduces LDL-C by approximately 8–10%. While direct reduction of cardiovascular events has not been demonstrated in long-term outcome trials, major bodies including EFSA and the European Atherosclerosis Society extrapolate cardiovascular risk reduction from the established LDL-C lowering effect. A controversy exists regarding whether elevated plasma phytosterol levels are themselves atherogenic, though observational data do not confirm this risk.

• pineScientific

  Pine bark extract (Pycnogenol) has been evaluated in multiple RCTs for cardiovascular outcomes. A 2024 review of 39 placebo-controlled trials confirmed benefits for cardiovascular health and endothelial function. A meta-analysis of RCTs found significant reductions in systolic (−3.22 mmHg) and diastolic (−1.91 mmHg) blood pressure. A double-blind, placebo-controlled crossover study in 23 patients with stable coronary artery disease showed Pycnogenol improved flow-mediated dilation by 32% vs. baseline. Evidence is promising but modest in effect size.

• pine barkScientific

  Pycnogenol exerts multiple validated cardiovascular effects: antihypertensive, antithrombotic, anti-atherosclerotic, and lipid-modifying. Eight separate RDP trials in the Frontiers 2024 review confirm cardiovascular benefits. Core mechanisms are eNOS activation, ACE inhibition, platelet aggregation inhibition, and endothelial function improvement.

• pineappleScientific

  Bromelain exerts fibrinolytic, antithrombotic, and anti-inflammatory effects on the cardiovascular system, including platelet aggregation inhibition and plasminogen activation. Pineapple's vitamin C and manganese provide antioxidant protection of vascular tissue. Early human cardiac studies documented near-complete thrombosis elimination.

• plant sterolsScientific

  Plant sterols are structurally similar to cholesterol and competitively inhibit its absorption in the small intestine, thereby lowering circulating LDL-cholesterol — a major cardiovascular risk factor. Multiple randomized controlled trials and meta-analyses confirm that ~2 g/day reduces LDL-C by approximately 10%. While the LDL-lowering effect is well-established, direct evidence of reduced hard cardiovascular events (e.g., myocardial infarction) from supplementation trials is still lacking. Both the FDA and EFSA have authorized health claims linking plant sterols/stanols to reduced cardiovascular disease risk via cholesterol reduction.

• plantagoScientific

  Plantago ovata (psyllium) has multiple clinically proven cardiovascular benefits: significant LDL-C and total cholesterol reduction, blood pressure lowering, and glycaemic improvement. A meta-analysis of 29 RCTs confirms cholesterol reduction. The FDA has approved a cardiovascular health claim for psyllium fiber.

• platycodonScientific

  Platycodon exhibits multiple cardiovascular-relevant actions including protection of vascular endothelium from oxidized LDL, antihypertensive activity in hypertensive rats, reduction of atherogenic lipids, and protection of cardiomyocytes from angiotensin II-induced apoptosis. These effects are supported by preclinical data.

• policosanolScientific

  Policosanol, a mixture of long-chain aliphatic alcohols derived primarily from sugarcane wax, has been investigated in multiple human clinical trials for cardiovascular benefits including lipid modification, blood pressure reduction, and antiplatelet activity. Early Cuban trials reported substantial LDL lowering and HDL raising, but independent non-Cuban trials have yielded inconsistent or null results on cholesterol endpoints. Evidence for modest blood pressure reduction and antiplatelet effects is supported by randomized controlled trials across multiple populations. The overall body of evidence is real but contested in effect size and consistency.

• pomegranateScientific

  Pomegranate has robust clinical and meta-analytic evidence supporting cardiovascular benefit, primarily through reductions in systolic and diastolic blood pressure, improvements in HDL cholesterol, and reductions in inflammatory markers. Key mechanisms include ACE inhibition, antioxidant activity via punicalagins, and anti-atherogenic effects on LDL oxidation and endothelial function. Evidence quality is moderate-to-good across multiple RCTs, though study heterogeneity and short durations remain limitations.

• pomeloScientific

  Pomelo bioactives act on multiple cardiovascular targets: naringin and naringenin reduce LDL, total cholesterol, and triglycerides; potassium supports blood pressure; and flavonoids inhibit vascular inflammation and atherogenesis. Animal studies show correction of diet-induced cardiovascular dysfunction. Pomelo peel oil has been studied for protection against cardiac ischemia-reperfusion injury.

• poppyScientific

  Papaverine from P. somniferum is a pharmaceutically established vasodilator used clinically for vasospasm, acute mesenteric ischemia, and erectile dysfunction. It relaxes vascular smooth muscle via phosphodiesterase inhibition. This represents a genuine pharmacological connection between poppy and the cardiovascular system.

• potassiumScientific

  Potassium is critical to cardiovascular function at multiple levels: maintaining cardiac action potential repolarization, regulating blood pressure via renal sodium handling and vascular tone, and reducing risk of stroke and arrhythmia. Epidemiological and RCT evidence is extensive and recognized by the FDA, AHA, and NIH ODS.

• prickly pear cactusScientific

  Human RCTs confirm Opuntia reduces multiple cardiovascular risk factors: LDL cholesterol, total cholesterol, triglycerides, systolic and diastolic blood pressure, and oxidative stress. Betalains protect LDL from oxidation and inhibit endothelial ICAM-1 expression in human studies.

• progesteroneScientific

  Progesterone receptors are present in cardiovascular tissues; progesterone has demonstrated short-term cardiovascular safety in RCT. It modulates blood pressure, lipid profiles (with a modest HDL reduction), and thromboembolic risk. Micronized progesterone carries a more favorable cardiovascular risk profile than synthetic progestins.

• pruneScientific

  Clinical trials demonstrate prunes improve multiple cardiovascular risk markers including LDL cholesterol, blood pressure, HDL, antioxidant capacity, and inflammatory biomarkers. Prune polyphenols inhibit LDL oxidation in vitro, a key step in atherogenesis. Both postmenopausal women and older men have been studied in RCTs.

• prunusScientific

  Prunus domestica (prunes/dried plums) provides clinically documented cardiovascular benefits via polyphenol-driven reductions in TC, LDL-c, inflammatory biomarkers (IL-6, TNF-α), and oxidative stress. Prunus africana phytosterols have structural cardiovascular relevance through cholesterol biosynthesis inhibition. Multiple human RCTs support cardiovascular risk factor improvement with prune consumption.

• psylliumScientific

  Psyllium has robust, multi-trial evidence for cardiovascular risk factor modification: it reduces LDL cholesterol, non-HDL cholesterol, apolipoprotein B, systolic blood pressure, triglycerides, and fasting blood glucose—all established CVD risk factors. A 2023 systematic review and meta-analysis of 28 RCTs (n=1,924) found significant reductions in LDL-C, non-HDL-C, and apoB. The FDA has authorized a cardiovascular disease risk-reduction health claim for psyllium.

• pterocarpus marsupiumScientific

  P. marsupium exerts anti-atherogenic, antihyperlipidemic, and antioxidant effects on the cardiovascular system in preclinical models, including reduction of aortic lipid infiltration, triglycerides, and MDA in high-fat diet-fed rats.

• pumpkinScientific

  Pumpkin seed oil modulates multiple cardiovascular risk factors—LDL cholesterol, blood pressure, arterial stiffness, and oxidative LDL modification—through its unsaturated fatty acid and phytosterol content. Human RCT data confirm reductions in systolic blood pressure and improvements in arterial hemodynamics in postmenopausal women.

• punarnavaScientific

  Preclinical studies have demonstrated cardioprotective, antihypertensive, and antihyperlipidemic actions of B. diffusa, targeting cardiac hypertrophy, oxidative stress, and vascular tone. The plant is traditionally classified under cardiac tonics in Ayurveda ('Hrudrogajit'). Human cardiovascular trials are lacking.

• purslaneScientific

  Multiple RCT meta-analyses demonstrate purslane significantly improves key cardiovascular risk markers: reducing triglycerides (−16.72 mg/dL), total cholesterol (−9.97 mg/dL), and CRP (−1.22 mg/L), while raising HDL-C (+4.09 mg/dL). Blood pressure reductions are also confirmed in RCT meta-analyses. Purslane's exceptional omega-3 content drives most cardiovascular benefits.

• pyrroloquinoline disodium saltScientific

  PQQ is cardioprotective in rodent ischemia/reperfusion models, reducing infarct size by ~50% and improving ventricular function. In humans, PQQ lowered CRP, IL-6, and lipid peroxides, and a clinical trial evaluated effects on serum triglycerides and LDL—all key cardiovascular risk markers.

• quercetinScientific

  Quercetin, a widely studied dietary flavonoid, has documented human clinical evidence supporting cardiovascular benefits including reductions in blood pressure, LDL-cholesterol, and inflammatory markers. Multiple randomized controlled trials and meta-analyses have been conducted, though results across studies are inconsistent. The strongest signal is a modest antihypertensive effect at supplemental doses, with mechanistic support from preclinical work on nitric oxide bioavailability, LDL oxidation inhibition, and endothelial function.

• quillajaScientific

  Quillaja saponins have been shown in a human clinical study to reduce total and LDL cholesterol in hypercholesterolemic patients. In vitro studies confirm the mechanism of reduced intestinal cholesterol bioaccessibility. Animal data also show triglyceride-lowering effects. No cardiovascular endpoint trials exist.

• quinoaScientific

  Multiple clinical trials and a 2022 meta-analysis confirm quinoa reduces total cholesterol, LDL-C, triglycerides, and blood pressure—all major cardiovascular risk markers. Quinoa's unsaturated fatty acids (linoleic acid), dietary fiber, bile acid-binding proteins, and anti-inflammatory polyphenols exert complementary cardioprotective mechanisms.

• radishScientific

  Radish extracts have demonstrated anti-atherosclerotic effects in ApoE-knockout mouse models, reducing triglycerides, LDL-cholesterol, and aortic plaque. Radish leaf extract lowered blood pressure in spontaneously hypertensive rats via nitric oxide elevation. Radish is a dietary source of nitrates, potassium, and flavonoids supporting vascular function.

• raspberryScientific

  Red raspberry polyphenols exert multiple cardiovascular-relevant effects including antioxidant protection of LDL, anti-inflammatory signaling in vascular tissue, reduction of cardiac fibrosis in animal heart failure models, and blood pressure support via potassium content. Human berry intervention studies have demonstrated improved antioxidant capacity and lipid profiles. A rat heart failure model showed raspberry polyphenols attenuated cardiac dysfunction via TLR4-mediated pathways.

• red cloverScientific

  Red clover isoflavones have demonstrated measurable effects on multiple cardiovascular parameters in human clinical trials. Improvements in arterial compliance and reductions in total vascular resistance are the most robustly evidenced outcomes. Effects on lipid profiles are mixed but multiple meta-analyses support total cholesterol reduction. Blood pressure effects are inconsistent in normotensive populations.

• red yeast riceScientific

  Red Yeast Rice (RYR) has robust clinical evidence for cardiovascular benefit, primarily through LDL cholesterol reduction. Its active compound, monacolin K, is chemically identical to lovastatin and inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Multiple RCTs and meta-analyses demonstrate significant reductions in LDL-C, total cholesterol, and hard cardiovascular endpoints including nonfatal myocardial infarction. The European Food Safety Authority (EFSA) has substantiated a health claim linking RYR monacolin K intake to plasma LDL-C reduction.

• rehmanniaScientific

  Rehmannia demonstrates cardiovascular and cerebrovascular protective activity through multiple mechanisms including antioxidant upregulation (Nrf2, HO-1), pro-inflammatory cytokine suppression, vascular endothelial protection, and anti-ischemic effects. Rehmannioside A specifically protects cerebral blood vessels and cardiac tissue in experimental models. Traditional TCM assigns Rehmannia to the heart channel.

• rehmannia glutinosaScientific

  Multiple pharmacological reviews confirm rehmannia glutinosa has documented actions on the cardiovascular system. Polysaccharide fractions exhibit cardioprotective and antioxidant activities, reduce vascular inflammation, and lower lipid levels. Vascular endothelial protective effects are attributed to catalpol and related compounds.

• reishi mushroomScientific

  Reishi has been used as a cardiovascular tonic in TCM for over 2,000 years and is among the most studied medicinal mushrooms for cardiovascular risk factors. Preclinical evidence shows LDL reduction, triglyceride lowering, antioxidative LDL protection, and anti-platelet activity. Human RCT evidence from a Cochrane review (2015) is inconclusive for surrogate markers; early human trials showed symptom relief in coronary artery disease patients.

• resveratrolScientific

  Resveratrol, a polyphenol found naturally in grapes and berries, has been evaluated in multiple human clinical trials and systematic reviews for cardiovascular benefit. Evidence from RCTs shows improvements in endothelial function (flow-mediated dilation) and reductions in inflammatory markers such as hs-CRP, though effects on blood pressure and heart failure endpoints remain inconsistent. Overall, the clinical evidence is promising but not yet conclusive, limited by small trial sizes, variable dosing, and low bioavailability.

• rhodiolaScientific

  Rhodiola rosea exerts multiple pharmacological effects on the cardiovascular system including antimyocardial ischemia-reperfusion protection, antithrombotic activity, antiarrhythmic effects, and lipid-lowering properties. These are supported by pre-clinical pharmacology, a 2022 PMC review, and a 2025 meta-analysis of clinical data from China. The EMA recognizes traditional use for stress-related symptoms with some clinical support.

• rhubarbScientific

  Rhubarb's anthraquinones and stilbenes exert documented cardiovascular effects including cholesterol and triglyceride reduction, anti-atherosclerotic activity, and antioxidant protection of vascular endothelium. Human clinical trials confirm lipid-lowering and arterial benefits. A 2025 PMC review specifically addressed rhubarb's multi-target anti-atherosclerotic mechanisms.

• rhubarb rootScientific

  Rhubarb root has documented effects relevant to cardiovascular health, including lipid reduction, blood pressure lowering, and anti-inflammatory action on vascular tissue. A human RCT found blood pressure reduction in diabetic patients, and a clinical trial found lipid reduction with rhubarb-containing tea.

• robusta coffeeScientific

  Habitual coffee consumption is associated in large prospective cohort studies with reduced cardiovascular mortality and all-cause mortality. Robusta coffee's CGA and antioxidant compounds improve endothelial function, reduce LDL oxidation, and exert anti-inflammatory effects on vascular tissue. A meta-analysis confirmed inverse associations between coffee consumption and cardiovascular mortality for both caffeinated and decaffeinated blends.

• roseScientific

  Rosehip has demonstrated clinically relevant cardiovascular benefits across multiple RCTs, including reductions in blood pressure, total cholesterol, and LDL. Antioxidant flavonoids and polyphenols protect vascular integrity and reduce atherosclerotic risk. Both Rosa canina and Rosa damascena have documented cardiovascular support in traditional medicine.

• rose hipsScientific

  Clinical RCT evidence shows that daily rose hip powder (40 g/day, 6 weeks) reduces systolic blood pressure, total cholesterol, LDL cholesterol, and calculated cardiovascular risk by 17% in obese individuals. Animal studies document antiatherosclerotic effects, reduced atherosclerotic plaque, and enhanced nitric oxide-mediated vascular dilation. Antioxidant polyphenols and high fiber content are proposed mechanisms.

• rosemaryScientific

  Rosemary demonstrates antithrombotic activity in human ex vivo studies and preclinical evidence shows blood pressure modulation, reduced cardiac oxidative stress, and protection of vascular endothelium. A first-in-human pilot trial showed antihypertensive signals from rosemary infusion in hypertensive patients. Traditional circulatory uses are strongly established.

• rosmarinic acidScientific

  Rosmarinic acid exerts cardioprotective and vascular effects including ACE inhibition, vasodilation, antioxidant protection of vascular endothelium, reduction of cardiac lipid peroxidation, and lipid-lowering activity in preclinical models. These mechanisms address multiple cardiovascular risk factors simultaneously.

• royal jellyScientific

  RJ modulates multiple cardiovascular risk factors in human RCTs: it lowers total cholesterol and LDL (confirmed by meta-analyses), reduces CRP and raises adiponectin, lowers diastolic blood pressure, and in animals retards aortic atherosclerosis. No long-term cardiovascular outcome trial exists.

• rubia cordifoliaScientific

  R. cordifolia has documented preclinical evidence for cardiovascular protection, including anti-platelet aggregation, vasodilation, calcium channel blocking activity, and potential prevention of atherosclerosis. Mollugin and rubiadin are the principal cardioactive constituents. The Ayurvedic Pharmacopoeia and multiple pharmacological reviews recognize its cardiotonic properties.

• rutinScientific

  Rutin exerts multiple cardiovascular effects: antithrombotic (PDI inhibition), antihypertensive, lipid-lowering, and endothelial-protective. Human RCTs demonstrate blood pressure and cardiometabolic improvements in diabetic populations. Its capillary-stabilizing properties support chronic venous disease management.

• ryeScientific

  Whole-grain rye supports cardiovascular health through multiple verified mechanisms: LDL-cholesterol reduction, improved endothelial function, blood pressure lowering, anti-inflammatory action, and reduced postprandial insulinemia. Clinical trials in metabolic syndrome patients and epidemiological cohorts support rye's role in reducing cardiovascular disease risk factors.

• safflowerScientific

  Safflower has the strongest scientific backing for cardiovascular applications among all its uses. Multiple studies document that safflower oil improves lipid profiles (reduced LDL, increased HDL) in human trials. HSYA protects cardiomyoblasts from LPS-induced apoptosis via JNK1/2-NF-κB pathway inhibition, and network pharmacology analyses identified 189 active compounds in safflower with 573 predicted targets relevant to coronary heart disease. Safflower extracts also reduce blood pressure in hypertensive animal models and retard myocardial injury post-infarction in dogs.

• saffronScientific

  Saffron exerts multiple protective effects on the cardiovascular system, including lipid lowering, blood pressure reduction, anti-atherosclerotic activity, and anti-inflammatory action on vascular endothelium. These are supported by 32 RCTs in a major 2022 meta-analysis. Crocin and crocetin are the primary active constituents responsible for cardioprotection.

• sarsaparillaScientific

  Smilax extracts have shown effects on multiple cardiovascular risk factors in animal studies, including reduction in blood pressure, hypertriglyceridemia, and insulin resistance. The volatile oil of S. glabra has demonstrated cardiovascular biological activity in pharmacological characterization. Evidence is preclinical; no human cardiovascular trials exist.

• schisandraScientific

  In vitro and animal studies show Schisandra lignans exert cardioprotective effects via anti-inflammatory, antioxidant, and metabolic pathways, and protect against doxorubicin-induced cardiotoxicity. Clinical research has investigated congestive heart failure, and a 2023 PMC review comprehensively documented cardiovascular-protective mechanisms. TCM lists the heart meridian as a primary target.

• schisandrinsScientific

  Schisandrin B demonstrates cardioprotective, anti-fibrotic, and antioxidant effects on the cardiovascular system in preclinical models. Korean and Chinese traditional medicine uses Schisandra to improve cardiovascular function and circulation. MSKCC and multiple PMC reviews document in vitro and animal cardioprotective evidence.

• scrophularia rootScientific

  The cardiovascular system is one of the primary targets of S. ningpoensis root pharmacology, with documented anti-ventricular remodelling, hypotensive, antiplatelet, vasodilative, and anti-cardiomyocyte apoptosis effects in preclinical studies. Cardiovascular protection is consistently described as among the most important pharmacological activities of Radix Scrophulariae.

• secoisolariciresinol diglucosideScientific

  SDG acts comprehensively across the cardiovascular system: reducing atherosclerosis, protecting myocardial cells from ischemia-reperfusion and iron overload–induced oxidative damage, improving endothelial function via eNOS/VEGF signaling, lowering LDL-C, and suppressing vascular inflammation via NF-κB inhibition. Multiple animal models and human observational and interventional data support cardiovascular system benefits.

• seleniumScientific

  Selenium is integral to cardiovascular system function via selenoproteins that protect vascular endothelium, cardiomyocytes, and platelets from oxidative damage and lipid peroxidation. Observational data show a nonlinear association between selenium status and cardiovascular disease risk, with benefit within a moderate selenium range. RCT evidence is mixed overall, but benefits have been observed in populations with low baseline selenium. Selenium deficiency is a recognized cause of Keshan disease, a potentially fatal cardiomyopathy.

• selenomethionineScientific

  Selenoproteins derived from selenomethionine reduce vascular oxidative stress, inhibit lipid peroxidation, and modulate platelet aggregation and inflammation, all relevant to cardiovascular function. RCT evidence is mixed: selenium alone shows no benefit in replete populations, but combined selenium plus CoQ10 supplementation reduced cardiovascular mortality in deficient elderly subjects over 10–12 years of follow-up.

• serratiopeptidaseScientific

  Serratiopeptidase has proposed fibrinolytic and anti-atherosclerotic effects relevant to the cardiovascular system, including potential degradation of arterial fibrin deposits and cholesterol-containing plaques. A 2023 PMC study demonstrated SRP attenuates LPS-induced vascular inflammation in a mouse model. However, no robust human RCTs for cardiovascular endpoints exist, and the Bhagat 2013 systematic review concluded cardiovascular/anti-atherosclerotic evidence is lacking.

• sesameScientific

  The cardiovascular system is the body system most extensively studied in relation to sesame. Multiple meta-analyses of RCTs confirm sesame reduces blood pressure, LDL cholesterol, total cholesterol, and triglycerides, while improving antioxidant status and reducing inflammatory markers. Sesame's lignans, PUFAs, phytosterols, and vitamin E collectively support cardiovascular function at multiple levels.

• shepherd's purseScientific

  Capsella bursa-pastoris has demonstrated cardiovascular-relevant pharmacological effects in preclinical studies including hypotensive activity (via rutin, choline, acetylcholine content), LDL cholesterol reduction via PCSK9 inhibition in obese mice, and cardioprotection against doxorubicin-induced toxicity through NRF2 pathway upregulation.

• shiitake mushroomScientific

  Eritadenine and beta-glucans in shiitake reduce LDL cholesterol and triglycerides; ergothioneine and lentinan reduce vascular oxidative stress and inflammation; adenosine inhibits platelet aggregation. Human RCT data show CRP reductions and lipid improvements. Shiitake's multi-target action on cardiovascular risk factors is among its best-documented effects.

• sichuan pepperScientific

  Z. bungeanum has demonstrated multiple cardiovascular-relevant pharmacological activities in preclinical models: lipid-lowering, anti-inflammatory, antioxidant, and antiatherosclerotic effects. TCM documents it as a circulation promoter. Human cardiovascular evidence is indirect (spicy food cohort studies).

• siliconScientific

  Silicon is a structural component of arterial walls, stabilizing elastin and collagen in the aorta. Aging and atherosclerosis reduce silicon concentrations in vascular tissue. Human and animal studies demonstrate that silicon supplementation can improve arterial elasticity, reduce stiffness, and lower blood pressure in individuals with elevated vascular aging markers.

• silk treeScientific

  A. julibrissin flavonoid extracts inhibit LDL oxidation in vitro, and triterpenoid saponins demonstrate cardioprotective activity in preclinical models. These effects provide a mechanistic basis for cardiovascular system protection, consistent with the plant's TCM use for palpitations and blood circulation.

• silymarinScientific

  Silymarin acts on multiple cardiovascular risk factors simultaneously: reducing LDL, triglycerides, total cholesterol, fasting glucose, and diastolic blood pressure in a 2024 meta-analysis of 33 RCTs. Anti-oxidative and anti-inflammatory mechanisms reduce LDL oxidation and vascular inflammation relevant to atherosclerosis progression.

• sitostanolScientific

  Sitostanol-based plant stanol esters have documented effects across multiple cardiovascular endpoints: they lower LDL cholesterol (5–15%), reduce apolipoprotein B, attenuate arterial stiffness and endothelial dysfunction, and are projected to reduce atherosclerotic cardiovascular disease incidence. These effects are substantiated by numerous randomised controlled trials and meta-analyses. The LDL-lowering effect is recognised in international dyslipidaemia guidelines.

• smartweedScientific

  P. hydropiper exerts preclinically demonstrated cardioprotective and antihypertensive effects, mediated largely by its flavonoid content (rutin, quercetin, isorhamnetin, kaempferol). Blood pressure reduction has been shown in hypertensive rodent models. Rutin is specifically known to strengthen vascular walls and improve capillary integrity.

• smilaxScientific

  Smilax flavonoids show cardiovascular-relevant activities including antioxidant protection of vascular cells, anti-inflammatory suppression of endothelial adhesion molecules, and S. glabra is noted in phytochemical reviews for cardiovascular protection potential. Astilbin has shown cardioprotective effects against ischemia-reperfusion injury via NF-κB blockade.

• sodiumScientific

  Sodium intake is a recognized cardiovascular risk factor, primarily through BP-mediated mechanisms but also through direct pathways including vascular damage, endothelial dysfunction, and oxidative stress. A meta-analysis of 36 studies involving over 600,000 participants examined the dose-response relationship between sodium intake and cardiovascular disease risk.

• solomon's sealScientific

  Polygonatum species have documented lipid-lowering, antioxidant, anti-inflammatory, and cardioprotective properties in animal and in vitro models, reviewed in a 2024 PMC study. TCM uses Polygonatum for coronary heart disease and cardiovascular tonification.

• sophoraScientific

  Sophora-derived rutin, quercetin, troxerutin, and oxymatrine target multiple cardiovascular pathways including ACE inhibition, vasodilation, platelet aggregation inhibition, cholesterol reduction, and capillary strengthening. Both species are recognized in TCM for cardiovascular and circulatory applications, with S. japonica listed in the European Pharmacopoeia.

• soursopScientific

  Soursop extracts exert antihypertensive and hypolipidemic effects in rodent cardiovascular models, reducing blood pressure, total cholesterol, LDL, VLDL, triglycerides, atherogenic index, and inflammatory cytokines. Antioxidant protection of vascular tissue is also documented.

• soyScientific

  Soy protein and isoflavones act through complementary mechanisms to benefit cardiovascular health: LDL and total cholesterol reduction, improved endothelial function, antioxidant activity, modest blood pressure lowering, and anti-inflammatory effects. These effects are documented across multiple RCTs and meta-analyses.

• soy isoflavonesScientific

  Soy isoflavones have multiple documented cardiovascular effects in human trials: modest LDL and total cholesterol reduction, HDL elevation, blood pressure lowering, and inverse associations with CVD risk. Effects are clinically modest but consistent across multiple meta-analyses.

• soybeanScientific

  Soy protein and isoflavones have been extensively studied for effects on the cardiovascular system, including LDL cholesterol reduction, modest blood pressure lowering in hypertensive individuals, anti-inflammatory effects, and improved endothelial function. The FDA approved a cardiovascular health claim for soy protein in 1999. Non-protein soy constituents including isoflavones, saponins, and fiber may provide additional cardiovascular benefits beyond cholesterol lowering.

• sphaeranthus indicusScientific

  S. indicus has demonstrated cardioprotective and vascular effects through anti-inflammatory inhibition of atherosclerosis, blood pressure reduction via nitric oxide pathways, and lipid profile improvements in clinical trials. The active compound 7-HF reduces aortic lesion area in animal models independent of lipid changes.

• spinachScientific

  Spinach's high nitrate content drives nitric oxide production, reducing blood pressure, arterial stiffness, and improving endothelial function. Its folate lowers homocysteine; its antioxidants protect against LDL oxidation and vascular inflammation. Multiple RCTs demonstrate clinically significant BP reductions and FMD improvements.

• spirulinaScientific

  Spirulina exerts broad cardiovascular system effects documented in human RCTs: reductions in blood pressure, total cholesterol, triglycerides, and LDL; increases in HDL; and decreases in endothelial damage biomarkers. A 2025 systematic meta-analysis of RCTs confirmed consistent positive clinical outcomes for cardiovascular risk factors. These effects are mediated through phycocyanin's antioxidant and anti-inflammatory actions on the vasculature, ACE-inhibitory peptides, and gamma-linolenic acid.

• SPMs (specialized pro-resolving mediators)Scientific

  SPMs resolve vascular inflammation, protect against atherosclerosis progression, prevent platelet aggregation, and reduce myocardial ischemia-reperfusion injury. Human biomarker studies confirm SPM deficiency in cardiovascular disease. The saliva leukotriene:RvD1 ratio predicts vascular disease in humans.

• squaleneScientific

  Squalene is metabolically integral to the cardiovascular system as a cholesterol biosynthesis intermediate transported in VLDL and LDL. It has antioxidant effects on lipoproteins, anti-inflammatory effects on vascular NF-κB signalling, and modest evidence from one human RCT of beneficial lipid effects and a separate trial of reduced arterial stiffness.

• steviaScientific

  Stevia has documented effects on multiple cardiovascular parameters: antihypertensive effects confirmed in human RCTs, anti-atherogenic effects in animal models, and inhibition of LDL oxidation in vitro. The cardiovascular system is among the most evidence-supported targets of stevia's bioactive glycosides.

• steviol glycosidesScientific

  Human RCT evidence demonstrates antihypertensive effects of higher-dose stevioside, with a confirmed significant systolic BP reduction in a meta-analysis of nine RCTs. In vitro and animal evidence shows SGs stabilize atherosclerotic plaque, reduce vascular oxidative stress, and protect cardiac cells.

• stigmasterolScientific

  Stigmasterol has dual and opposing cardiovascular effects documented scientifically: at dietary levels it is associated with cholesterol lowering and potential cardioprotection; at accumulating levels (phytosterolemia), it causes cardiac fibrosis, left ventricular dysfunction, and increased mortality in rodent models. This complexity is important for accurate characterization.

• strawberryScientific

  Strawberry polyphenols exert multiple favorable effects on the cardiovascular system, including improved endothelial function, reduced arterial stiffness, lowered atherogenic LDL particles, reduced CRP, and upregulated nitric oxide production. Clinical trial and epidemiological evidence consistently supports a cardioprotective role. The Iowa Women's Health Study found an inverse association between strawberry intake and cardiovascular mortality over 16 years.

• succinic acidScientific

  Succinate is a recognized biomarker and signaling molecule in cardiovascular disease, accumulating during ischemia and driving ischemia-reperfusion injury via ROS generation at Complex II upon reperfusion. Pre-ischemic succinate supplementation has been shown to protect isolated rat hearts and improve post-ischemic cardiac function. Via SUCNR1 and the succinate/IL-1β axis, it also modulates endothelial inflammation in atherosclerosis.

• sulforaphaneScientific

  Sulforaphane protects the cardiovascular system through Nrf2-driven endothelial antioxidant defense, NF-κB-mediated vascular anti-inflammation, improved lipid profiles, and reduced atherosclerotic risk biomarkers. Multiple human RCTs in T2DM patients show improvements in cardiovascular risk biomarkers.

• sunflowerScientific

  Sunflower seed oil and seeds provide well-documented cardiovascular benefits including reduced LDL cholesterol, triglycerides, and blood pressure in human clinical trials. Vitamin E from sunflower protects against LDL oxidation. Linoleic acid in sunflower is associated with 15% lower risk of cardiac events and 21% lower cardiovascular mortality in epidemiological data.

• sunflower oilScientific

  Dietary sunflower oil exerts multiple effects on the cardiovascular system via its fatty acid profile: lowering LDL cholesterol and triglycerides, modestly raising HDL, and reducing LDL oxidation susceptibility. These effects are most consistent in dyslipidemic populations and with high-oleic varieties. The FDA has recognized a qualified health claim for oleic acid in high-oleic sunflower oil and reduced coronary heart disease risk.

• sweet flagScientific

  Preclinical studies demonstrate cardiac depressant, coronary vasodilatory, antihypertensive, and hypolipidemic effects. A PubMed-indexed study (2012) characterized EDHF-mediated coronary vasodilation. An Ayurvedic clinical study in ischemic heart disease patients reported cardiovascular improvements.

• szechuan lovageScientific

  The cardiovascular system is the most extensively documented target of Szechuan lovage. CX bioactives act on blood vessels, platelets, cardiac muscle, and the endothelium, with evidence spanning atherosclerosis, myocardial ischemia, angina, hypertension, and thrombus prevention. Multiple clinical trials and a 2025 comprehensive review confirm its multi-mechanism cardiovascular efficacy.

• taurineScientific

  Taurine has substantial clinical and mechanistic evidence supporting its role in cardiovascular health. Multiple randomized controlled trials and meta-analyses demonstrate reductions in blood pressure, improved cardiac function in heart failure patients, and favorable effects on lipid profiles. Its primary mechanisms include intracellular calcium modulation, nitric oxide-mediated vasodilation, inhibition of the renin–angiotensin–aldosterone system, and antioxidant/anti-inflammatory activity. Evidence quality is moderate; most trials are small and short-term, and results remain somewhat inconsistent across studies.

• terminaliaScientific

  Terminalia arjuna and T. chebula have the strongest and best-documented evidence for the cardiovascular system. Multiple clinical trials support anti-ischemic, antihypertensive, hypolipidemic, anti-atherogenic, and positive inotropic effects. Systematic reviews and meta-analyses confirm cardiovascular benefit, particularly in coronary artery disease, heart failure, and dyslipidemia.

• tetrahydro iso-alpha acidsScientific

  THIAA combined with niacin inhibited TNF-α-induced cytokines in human aortic endothelial cells and THP-1 monocytes in vitro, and in a 12-week pilot RCT in 11 dyslipidemic subjects (125 mg THIAA + 500 mg niacin), produced a clinically relevant increase in flow-mediated vasodilation (FMD) vs. placebo. THIAA also inhibits monocyte-endothelial cell interactions relevant to atherosclerosis.

• tinospora cordifoliaScientific

  T. cordifolia exerts cardioprotective and antiarrhythmic effects in preclinical models, normalizing ECG parameters and electrolyte balance. It also reduces cardiovascular risk factors including triglycerides, cholesterol, and VLDL in both animal and human studies. Traditional Ayurveda describes it as a cardiotonic.

• TMG (trimethylglycine)Scientific

  TMG directly modulates the cardiovascular system by lowering plasma homocysteine—a validated cardiovascular risk biomarker—through the BHMT enzyme pathway in the liver. FDA-approved prescription betaine treats homocystinuria, a genetic disorder causing severe premature cardiovascular disease. In broader populations, TMG consistently lowers homocysteine at 4–6 g/day but has not demonstrated hard cardiovascular event reduction and may adversely affect lipid profiles at higher doses.

• tocotrienolsScientific

  Tocotrienols are among the most extensively studied natural compounds for cardiovascular health, with clinical evidence for cholesterol lowering, triglyceride reduction, anti-inflammatory cytokine suppression, endothelial support, and attenuation of arterial lesion progression. Multiple RCTs and meta-analyses support cardiovascular biomarker benefits.

• tomatoScientific

  Tomato and lycopene have the most extensive evidence base in the cardiovascular system, with multiple systematic reviews and meta-analyses demonstrating reduced CVD risk, lower stroke incidence, improved blood pressure, reduced LDL, decreased endothelial dysfunction, and antiplatelet activity in clinical populations.

• trans-geranylgeraniolScientific

  GGOH supports cardiovascular health by serving as the obligatory precursor for endogenous CoQ10 synthesis, a molecule critical for myocardial energy production and antioxidant defense. It also contributes to vitamin K2 (MK-4) synthesis, which inhibits vascular calcification. Statin-induced GGOH depletion is mechanistically linked to impaired cardiac mitochondrial function.

• trans-pterostilbeneScientific

  Trans-pterostilbene acts on multiple cardiovascular targets: reducing blood pressure (confirmed in human RCT), modulating cholesterol pathways (PCSK9/LDLR), inhibiting platelet aggregation, reducing endothelial inflammation, and protecting cardiomyocytes via AMPK/SIRT1/PGC-1α pathways.

• tribulusScientific

  Tribulus influences the cardiovascular system through multiple documented mechanisms: ACE inhibition, nitric oxide-mediated vasodilation, anti-atherosclerotic saponin effects, and lipid lowering in human RCTs. Traditional use for blood pressure and angina is supported by preclinical evidence.

• trichosanthesScientific

  Trichosanthis Fructus is documented as having pharmacological activities that 'mainly affect the cardiovascular system,' with effects including protection against myocardial ischemia, calcium antagonism, endothelial cell protection, anti-hypoxic, and anti-platelet aggregation activities. It is used in clinical practice in China for a range of cardiovascular conditions. The peel extract inhibits NF-κB, a key cardiovascular inflammatory pathway.

• triphalaScientific

  Triphala exerts documented cardioprotective effects including reducing LDL-cholesterol, total cholesterol, and triglycerides in 6 of 12 RCTs (749 total patients), improving HDL-C, and demonstrating myocardial protective properties in preclinical models. Its lipid-lowering mechanism involves HMG-CoA reductase inhibition and reduced cholesterol absorption.

• turmericScientific

  Curcumin exerts documented benefits on multiple cardiovascular risk parameters including LDL cholesterol, triglycerides, blood pressure, endothelial function, and systemic inflammation. Meta-analyses of RCTs confirm significant reductions in LDL-C and blood pressure. The evidence base spans lipid management, hypertension, atherosclerosis, and cardiac biomarkers.

• ubiquinolScientific

  Ubiquinol has extensive clinical evidence supporting its role in cardiovascular health, including heart failure management, blood pressure reduction, endothelial function improvement, and LDL oxidation prevention. Large RCTs (Q-SYMBIO), multiple meta-analyses, and the ubiquinol-specific endothelial function trial all document clinically meaningful effects. Ubiquinol is the preferred bioavailable form for cardiovascular patients.

• urolithin aScientific

  UA has demonstrated effects on cardiovascular biomarkers in humans, including reduction of plasma ceramides (cardiovascular disease risk markers) in a 4-month RCT. Preclinical data support cardioprotective, anti-atherosclerotic, and vasculoprotective mechanisms. A pilot human heart failure RCT found HDL-c improvement but no significant echocardiographic benefit.

• valerian rootScientific

  A 2016 PMC review of the cardiovascular activities of Valeriana species documented vasorelaxant, antihypertensive, antiarrhythmic, and anti-ischemic properties in preclinical models. Constituent valerenol lowers heart rate and blood pressure stimulated by adrenaline, dilates coronary arteries, and inhibits vascular smooth muscle contraction. Valepotriate-containing hexanic extracts produced endothelium-independent relaxation in isolated rat aorta. Human clinical evidence for these cardiovascular effects is largely absent.

• vanadiumScientific

  Vanadium compounds act on the cardiovascular system through Akt-mediated signaling, conferring cardioprotection in ischemia/reperfusion models, reducing cardiac hypertrophy, and modulating vascular smooth muscle. Secondary cardiovascular benefits accrue from improvements in lipid profiles, blood glucose, and blood pressure in diabetic and hypertensive animal models.

• vitamin B1Scientific

  Wet beriberi—cardiovascular thiamine deficiency—causes high-output heart failure, peripheral vasodilation, tachycardia, and edema. The cardiovascular system is among the two organ systems most sensitive to thiamine deficiency. Clinical recovery with thiamine repletion is well documented.

• vitamin B12Scientific

  Vitamin B12 plays a role in cardiovascular health primarily through its function in homocysteine metabolism: deficiency elevates plasma homocysteine, an established cardiovascular risk marker linked to endothelial dysfunction, atherosclerosis, and thrombogenesis. While B12 supplementation reliably lowers homocysteine levels, clinical trials have not consistently demonstrated a corresponding reduction in hard cardiovascular endpoints such as myocardial infarction or overall CVD mortality. The evidence is therefore scientifically grounded but mechanistically incomplete — the surrogate benefit (homocysteine lowering) does not straightforwardly translate to clinical benefit.

• vitamin B2Scientific

  Riboflavin helps maintain normal blood homocysteine levels, a recognized cardiovascular risk factor, via its role as FAD cofactor for MTHFR. In individuals with the MTHFR 677TT genotype, riboflavin supplementation lowers both homocysteine and blood pressure in RCTs. Riboflavin's coenzymes FAD and FMN are also critical for cardiac energy metabolism.

• vitamin B3 (niacin)Scientific

  Niacin (Vitamin B3) has extensive clinical evidence for modifying cardiovascular risk factors, primarily by raising HDL-cholesterol and lowering LDL-cholesterol and triglycerides. The landmark Coronary Drug Project demonstrated reduced nonfatal myocardial infarction and a long-term mortality benefit with niacin monotherapy. However, modern randomized trials (AIM-HIGH, HPS2-THRIVE) found no incremental reduction in cardiovascular events when niacin was added to statin therapy, and recent research identifies excess niacin metabolites as potential promoters of vascular inflammation.

• vitamin B5Scientific

  Pantethine (a vitamin B5 derivative) has demonstrated favorable effects on the cardiovascular lipid profile across multiple RCTs, reducing LDL, total cholesterol, and triglycerides while raising HDL. Additionally, pantothenic acid is proposed to reduce low-grade vascular inflammation via antioxidant effects on C-reactive protein.

• vitamin B6Scientific

  Vitamin B6 is mechanistically linked to cardiovascular health primarily through its role in homocysteine metabolism via the transsulfuration pathway, where its active form (pyridoxal-5'-phosphate, PLP) serves as a coenzyme for cystathionine β-synthase. Epidemiological data associate low plasma PLP with higher coronary heart disease risk, and some cohort studies link higher dietary B6 intake to lower CVD incidence. However, multiple large randomized controlled trials—including NORVIT, WENBIT, and a 5,442-woman RCT—found that B6 supplementation alone did not reduce cardiovascular events, despite lowering homocysteine. The relationship is well-studied but clinically unresolved: a clear biochemical mechanism exists, yet intervention trials have not demonstrated that supplementation translates to reduced cardiovascular outcomes.

• vitamin B9 (folate)Scientific

  Vitamin B9 (folate) has a well-documented mechanistic and clinical relationship with cardiovascular health, primarily through its role in lowering plasma homocysteine, a recognized independent risk factor for atherosclerotic vascular disease. Clinical evidence demonstrates a consistent benefit for stroke reduction, particularly in folate-deficient populations, while evidence for coronary heart disease prevention is weaker and more mixed. The effect is highly population-dependent, with benefits most pronounced in those with low baseline folate or elevated homocysteine.

• vitamin B9 (methylfolate/5-MTHF)Scientific

  Vitamin B9 as 5-methyltetrahydrofolate (5-MTHF) supports the cardiovascular system through two well-documented mechanisms: lowering plasma homocysteine (an independent cardiovascular risk factor) and directly improving endothelial function by enhancing eNOS coupling and nitric oxide (NO) bioavailability. Clinical and mechanistic studies published in peer-reviewed journals confirm both pathways. However, while homocysteine reduction by folate is robust, large RCTs and meta-analyses show this does not consistently translate into reduced hard cardiovascular events in already-diseased populations.

• vitamin CScientific

  Vitamin C improves endothelial function and nitric oxide bioavailability, and has shown modest blood-pressure-lowering effects in short-term RCTs. Large-scale RCT evidence for reducing hard CVD outcomes (MI, stroke) is limited and of low quality. Epidemiological data associate higher vitamin C intake with reduced cardiovascular risk.

• vitamin DScientific

  Substantial observational and mechanistic evidence links vitamin D status to cardiovascular health, with low 25(OH)D consistently associated with increased risk of hypertension, coronary artery disease, heart failure, and cardiovascular mortality. Proposed mechanisms include modulation of the renin-angiotensin-aldosterone system (RAAS), endothelial function, inflammation, and cardiomyocyte calcium handling. However, large randomized controlled trials — most notably the VITAL trial (n=25,871, NEJM 2019) — have not demonstrated that supplementation reduces major cardiovascular events in the general population. The current consensus characterizes vitamin D deficiency as a marker of cardiovascular risk rather than a confirmed causal therapeutic target.

• vitamin D3Scientific

  Substantial observational and mechanistic evidence links vitamin D3 deficiency to increased cardiovascular disease risk, including hypertension, atherosclerosis, and heart failure. Proposed mechanisms include downregulation of the renin-angiotensin-aldosterone system, improved endothelial function, and reduced inflammation. However, large randomized controlled trials—most notably the VITAL trial—have not demonstrated that vitamin D3 supplementation reduces major cardiovascular events in generally healthy populations. The overall evidence base is robust in epidemiological and mechanistic terms but inconclusive for supplementation-based therapeutic benefit.

• vitamin EScientific

  Vitamin E's relationship with the cardiovascular system is extensively studied but contradictory. Observational cohort studies support a cardioprotective role via antioxidant inhibition of LDL oxidation and atherosclerosis. Large RCTs have generally failed to reduce cardiovascular events with supplementation, and some high-dose trials showed adverse outcomes.

• vitamin KScientific

  Vitamin K—particularly vitamin K2 (menaquinone)—plays a documented role in cardiovascular health through its activation of Matrix Gla Protein (MGP), the body's principal inhibitor of vascular calcification. Observational studies, including the large Rotterdam Study, associate higher dietary vitamin K2 intake with reduced coronary heart disease risk, lower aortic calcification, and reduced cardiovascular mortality. Randomized controlled trials have produced mixed but partially supportive results, particularly in slowing arterial calcification progression in higher-risk populations. The overall evidence base is graded as promising but not yet definitive, as well-powered RCTs with hard cardiovascular endpoints remain limited.

• wasabiScientific

  Wasabi/6-MSITC supports cardiovascular health through multiple complementary mechanisms: antiplatelet activity, endothelial Nrf2/HO-1 activation, antihypertensive effects, reductions in cholesterol and triglycerides, and suppression of vascular inflammation. These effects have been characterized in vitro and in animal models of metabolic syndrome and are supported by a 2024 systematic review.

• watercressScientific

  Human RCT data show watercress supplementation reduces triglycerides (~10%), modestly reduces LDL and total cholesterol, and raises plasma antioxidant carotenoids associated with reduced cardiovascular mortality. The 2025 PRISMA systematic review of 7 RCTs confirmed antioxidant and lipid-modulating effects relevant to cardiovascular risk. Dietary nitrate content provides additional vasodilatory support.

• watermelonScientific

  Watermelon exerts multi-target cardiovascular benefits: L-citrulline improves NO-mediated vasodilation and reduces arterial stiffness and blood pressure; lycopene reduces LDL oxidation, triglycerides, and vascular inflammation. Multiple RCTs confirm cardiovascular risk factor improvements with watermelon or its concentrated bioactives.

• wheatScientific

  Whole-grain wheat exerts multiple effects on the cardiovascular system, including blood pressure reduction, modest LDL cholesterol lowering, anti-inflammatory effects via polyphenols, and improved vascular function. Prospective cohort data consistently show lower cardiovascular disease risk with higher whole-grain wheat intake. RCTs confirm blood pressure reduction as the most reliable clinical outcome.

• wheat germScientific

  Wheat germ supports cardiovascular health through phytosterols (inhibiting cholesterol absorption), dietary fiber (supporting lipid regulation), vitamin E (reducing oxidative LDL modification), and omega-3 fatty acids (anti-inflammatory). Human RCT data show mixed results: modest total cholesterol reduction in T2DM patients but null results in healthy adults at lower doses.

• wheat grassScientific

  Human RCT evidence documents significant reductions in total cholesterol, LDL, triglycerides, and ApoB in hyperlipidemic women taking wheatgrass. Anti-inflammatory effects on vascular tissue are shown in preclinical models. Wheatgrass contributes potassium and magnesium relevant to vascular tone.

• whey proteinScientific

  Whey protein exerts multiple verified effects on the cardiovascular system: reducing systolic blood pressure via ACE-inhibitory peptides, lowering LDL-cholesterol and triglycerides, improving endothelial function (FMD), and improving microvascular function in heart failure patients. A 2025 meta-analysis of 21 RCTs in Clinical Nutrition confirmed these cardiometabolic effects. The Whey2Go RCT demonstrated significant 24-hour ambulatory BP reductions and improved vascular function markers.

• yarrowScientific

  Yarrow exerts multiple cardiovascular pharmacological actions: antihypertensive, vasorelaxant, anti-arrhythmic, antiplatelet, and vasoprotective effects are documented in preclinical models. The sesquiterpene lactones leucodin and achillin are identified as key bioactive cardiovascular agents.

• yeastScientific

  Brewer's yeast supplementation has demonstrated favorable effects on multiple cardiovascular risk factors in human clinical trials: reducing LDL-C, triglycerides, and blood pressure while raising HDL-C. GTF-chromium, ACE-inhibitory peptides, and the mineral content of yeast are the primary proposed mechanisms. Evidence is preliminary and predominantly from diabetic populations.

• yerba mateScientific

  Human trials show yerba mate reduces blood pressure, lowers LDL-cholesterol in dyslipidemic populations, increases HDL-associated antioxidant enzyme PON-1, and reduces inflammatory cytokines. Large observational data associate heavy YM consumption with lower cardiovascular disease self-reporting.

• yohimbeScientific

  Yohimbine has pronounced, well-characterized effects on the cardiovascular system, mediated through α2-adrenergic receptor blockade increasing norepinephrine and sympathetic activation. It raises heart rate and blood pressure in a dose-dependent manner, increases forearm blood flow at rest, and has been studied as a treatment for neurogenic orthostatic hypotension. It can also pose cardiovascular risk, particularly combined with other stimulants.

• yuccaScientific

  Yucca phenolics (resveratrol, yuccaols A–E) have demonstrated antiplatelet activity in human blood platelet in vitro studies, inhibiting adhesion, aggregation, and ROS generation. Saponins reduce cholesterol absorption, benefiting the lipid component of cardiovascular risk. A human study showed LDL cholesterol reduction, and clinical reports note blood pressure reduction. Overall cardiovascular protection via multiple mechanisms is supported.

• zanthoxylumScientific

  Zanthoxylum species influence cardiovascular health through hypolipidemic, antioxidant, and antihypertensive effects demonstrated in preclinical models. Z. heitzii extract prevented atherosclerotic plaque formation; Z. bungeanum compounds inhibited HMG-CoA reductase; Z. tessmannii attenuated L-NAME-induced hypertension and protected cardiac tissue.

• zeaxanthinScientific

  Serum zeaxanthin (combined with lutein) is inversely associated with cardiovascular disease prevalence and CVD mortality in large observational studies. A DBPC trial found xanthophyll supplementation reduced oxidized LDL and pro-inflammatory cytokines linked to atherosclerosis initiation. The AREDS2 RCT, however, found no reduction in hard CVD events, highlighting the gap between biomarker and clinical outcome evidence.

• zincScientific

  Multiple clinical and epidemiological studies demonstrate a meaningful relationship between zinc status and cardiovascular health. Low serum zinc is consistently associated with increased risk of coronary artery disease, heart failure, and adverse cardiovascular events. Randomized controlled trial meta-analyses show zinc supplementation improves lipid profiles (reducing total cholesterol, triglycerides, and LDL) and modestly reduces systolic blood pressure. The evidence base is substantial but heterogeneous, and effect sizes vary by population and dose.

• abies spectabilisTraditional

  A. spectabilis is traditionally used in hypotensive conditions, indicating folk medicine use for cardiovascular/blood pressure regulation. Preclinically confirmed antiplatelet activity is also pharmacologically relevant to cardiovascular health.

• alkanetTraditional

  Alkanet is traditionally used externally for phlebitis and varicose veins, and a combination preparation with Pistacia atlantica, olive oil, and laurel resin is documented in traditional Bedouin/Palestinian medicine for treating blood clots in the legs. These vascular indications appear consistently in ethnobotanical records but have no clinical trial support.

• alpinia galangalTraditional

  A. galanga is used in TCM to invigorate circulation and reduce heart-related discomforts, with traditional indications including heart disease. Constituents act as PAF antagonists and demonstrate hypolipidaemic activity in animal models. The plant has been traditionally listed for cardiovascular-related conditions.

• amberTraditional

  TCM documents amber's use for cardiovascular conditions including angina, arrhythmia, and palpitations via its blood-invigorating action. Succinic acid is proposed to regulate cardiomyocyte function and inhibit platelet aggregation. No clinical trials evaluate amber for cardiovascular outcomes.

• arnicaTraditional

  Historical European folk medicine used arnica internally as a cardiovascular stimulant and circulatory aid, and the EMA assessment report documents traditional use for cardiovascular conditions. Internal use has been abandoned due to toxicity. Helenalin inhibits platelet function via thiol-dependent pathways, a pharmacologically relevant cardiovascular effect observed in vitro.

• asparagusTraditional

  Asparagus has documented traditional use for cardiovascular conditions across Eastern European, Asian, and Chinese medicine, with pharmacopoeial recognition. Preclinical studies show ACE-inhibitory, antihypertensive, hypolipidemic, and antioxidant cardiovascular-relevant effects. A small human trial showed improvements in blood pressure and cholesterol with asparagus powder intake.

• bacopaTraditional

  Bacopa has traditional use as a cardiac tonic in India and Pakistan. Preclinical studies show arterial relaxation, protection against myocardial ischemia/reperfusion injury, increased coronary flow, and antioxidant protection of cardiac tissue. No human cardiovascular RCTs have been conducted.

• biota seedTraditional

  Biota seed enters the Heart meridian in TCM and is used in classical formulas targeting cardiovascular symptoms such as palpitations and restlessness. A 2025 RSC pharmacological summary lists anti-arteriosclerosis among Semen Platycladi's documented pharmacological effects. Human cardiovascular evidence is absent.

• boswelliaTraditional

  Ayurvedic texts listed Boswellia as supportive for cardiovascular diseases. In vitro evidence shows boswellic acids exert anti-inflammatory effects on endothelial cells and possess antithrombotic activity, but no human cardiovascular RCT has been published.

• clematisTraditional

  Clematis vitalba has been traditionally associated with vasodilatory and circulatory effects in European folk medicine, attributed to flavonoids and phenolic acids. TCM also records C. armandii ('mu tong') as opening blood vessels and promoting circulation. No clinical cardiovascular studies exist for Clematis.

• european elderTraditional

  Elderberry polyphenols—particularly anthocyanins—are associated with cardiovascular protection through antioxidant, anti-inflammatory, and lipid-regulating mechanisms in animal models and epidemiological reviews. Blood pressure reduction and improved lipid profiles have been demonstrated in hypertensive animal models. Human RCT data specifically for cardiovascular endpoints are absent.

• goldenrodTraditional

  Goldenrod has documented antihypertensive effects in animal models and cardioprotective effects characterized in preclinical studies. Flavonoids (especially rutin) support vascular endothelial integrity. A PMC study (2024) found that S. microglossa extract mitigated cardiovascular dysfunction in hypertensive rats. Human cardiovascular trials are absent.

• hedychium spicatumTraditional

  H. spicatum is documented in Ayurvedic tradition for heart diseases and blood purification. Preclinical data indicate hypotensive properties, and the plant is an ingredient in PADMA-28, a Tibetan polyherbal preparation studied for cardiovascular indications including peripheral vascular disease. Antioxidant properties support cardiovascular relevance.

• horseradishTraditional

  Horseradish is traditionally classified as a circulatory stimulant. Animal data suggest hypotensive effects via prostaglandin-mediated pathways. Research on AITC identifies cardiovascular health benefits from anti-inflammatory vascular protection. No human clinical trials exist for cardiovascular endpoints with horseradish.

• immortelleTraditional

  H. italicum EO is traditionally attributed with anticoagulant and circulatory-toning properties in Mediterranean aromatherapy, and is used for varicose veins, spider veins, and bruises. A randomised human study found H. italicum infusion reduced body mass and fat mass in metabolic syndrome patients. No cardiovascular clinical trial evidence exists.

• indian frankincenseTraditional

  Traditional Ayurvedic and Unani texts document Boswellia for cardiovascular conditions. Anti-atherogenic activity has been demonstrated in animal models. Anti-hyperlipidaemic and anti-inflammatory effects in clinical trials are relevant to cardiovascular risk but no dedicated cardiovascular outcome RCT exists.

• lilyTraditional

  In TCM, lily bulb is said to act on the Heart meridian, indicated for palpitations and emotional disturbances affecting the heart. The Chinese Pharmacopoeia lists palpitations as a classical indication. Na⁺/K⁺-ATPase inhibition by steroidal saponins has been noted as a newly discovered pharmacological activity potentially relevant to cardiac physiology. No human cardiovascular trials exist.

• malabar nutTraditional

  Cardioprotective and moderate hypotensive activity are documented in pharmacological reviews of A. vasica. Traditional Ayurvedic use lists heart troubles. Antioxidant flavonoids (quercetin, kaempferol) in the plant have established cardiovascular protective properties.

• milkweedTraditional

  Milkweed species contain cardenolide cardiac glycosides structurally similar to digoxin, and were traditionally used for heart conditions. Asclepias asperula was specifically used for heart conditions in Southwestern Indigenous tradition. The cardiac glycoside content was recognized in early American pharmacy as having digitalis-like actions. Preclinical pharmacological data exist but no clinical trials.

• polygalaTraditional

  P. tenuifolia is classified as a cardiotonic in TCM, Kampo, and Korean traditional medicine, used for palpitations and heart-kidney disharmony. Preclinical isolated-heart studies document antiarrhythmic and cardioprotective properties. No human cardiovascular trials exist.

• polygala rootTraditional

  Contemporary pharmacological reviews identify cardiovascular activity as a documented pharmacological category of Polygala root. Traditional TCM use includes 'cardiotonic' properties and treatment of palpitations. Preclinical data show antioxidant and anti-inflammatory effects relevant to cardiovascular protection.

• polyporusTraditional

  P. umbellatus is noted in reviews to enhance microcirculation, and Wulingsan formulas containing it modulate the renin–angiotensin–aldosterone system in animals. Its strong diuretic action reduces fluid load relevant to cardiovascular edema. No dedicated CV clinical trials have been conducted.

• prickly ashTraditional

  Prickly ash is traditionally recognized as a cardiovascular and circulatory tonic, with Eclectic medical texts noting that it 'strengthens the action of the heart' and 'slightly quickens the pulse.' The constituent nitidine has been cited for cardiovascular tonic effects. The 2024 PMC Frontiers review notes preclinical evidence for cardiovascular benefit in inflammatory models.

• skullcapTraditional

  S. baicalensis is clinically applied in China for hypertension and cardiovascular disease. Baicalin has demonstrated effects against atherosclerosis, myocardial ischemia, and hypertension in preclinical research. S. lateriflora was prescribed for cardiac conditions of the 'nervous type' in Eclectic medicine.

• sumaTraditional

  Suma's saponin and phytosterol content is traditionally associated with cardiovascular support, including improved circulation and anti-inflammatory protection of the heart. Ecdysteroids have been noted in patent literature to improve myocardial contraction and stabilize cardiac cell membranes. No human cardiovascular clinical trials have been published.

• white willowTraditional

  White willow bark inhibits platelet aggregation to a lesser degree than aspirin through salicylate-mediated COX pathways, and its polyphenol/tannin content has been associated with potential cardiovascular protective properties. These effects are documented in ex vivo and in vitro studies but lack human cardiovascular outcome trials. Drug-interaction guidance recognizes its antiplatelet activity as clinically relevant.

• wild yamTraditional

  Wild yam has been used in Russian and traditional herbal medicine as a vasodilator and cardiac sedative. Dioscorin proteins from Dioscorea species showed hypotensive effects in animal models. A small human clinical trial found raised HDL cholesterol with Dioscorea extract. However, the only well-controlled human trial (Komesaroff 2001) found no cardiovascular parameter changes.

• wood betonyTraditional

  Wood betony has traditional use as a cardiovascular tonic, attributed to hypotensive glycosides, cholagogue properties, and mild circulatory stimulation. It is used in herbal formulas for hypertension-related conditions. No human RCT data exist.